Skip to the page
Get started – free

Data / Research funding / Prostate Disease

Prostate Disease: 465 NIH awards ($757.7M) to 138 organizations

465 NIH awards ($757.7M) in the NIH spending category Prostate Disease, to 138 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.

SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.

Get awards on Prostate DiseaseWatch Prostate Disease
Topic
NIH spending category

Awards

465 awards in the window.

AwardAgencyInstitute or divisionFiscal yearAmount in windowStartEndPrincipal investigatorSource
NCI Early Career Cancer Clinical Investigator AwardNIHNational Cancer Institute2021 to 2025$65,560,307March 10, 1997November 30, 2026EBERT, BENJAMIN LEVINEreporter.nih.gov
The Pacific Northwest Prostate Cancer SPORENIHNational Cancer Institute2021 to 2025$9,924,776September 19, 2002August 31, 2028NELSON, PETER Sreporter.nih.gov
Cancer Epidemiology Cohort in Male Health ProfessionalsNIHNational Cancer Institute2021 to 2025$7,706,351August 21, 2012July 31, 2027MUCCI, LORELEIreporter.nih.gov
University of Arizona Cancer Prevention Clinical Trials NetworkNIHNational Cancer Institute2021 to 2025$7,572,043August 16, 2019July 31, 2031THOMPSON, PATRICIA ANNreporter.nih.gov
iCAN PREVENT: MD Anderson International Cancer Prevention Clinical Trials ConsortiumNIHNational Cancer Institute2021 to 2025$7,046,172August 15, 2019July 31, 2031VILAR SANCHEZ, EDUARDOreporter.nih.gov
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer CareNIHNational Cancer Institute2021 to 2025$5,422,908March 5, 2019February 28, 2026BURSTEIN, HAROLD JOHNreporter.nih.gov
Genomic and Genomic Variation in Prostate CancerNIHNational Cancer Institute2022 to 2025$5,164,514January 7, 2022April 30, 2027REBBECK, TIMOTHY RICHARDreporter.nih.gov
Human Prostate Tumor Atlas CenterNIHNational Cancer Institute2024 to 2025$5,162,603September 1, 2024August 31, 2029DING, LIreporter.nih.gov
Integrating targeted therapy and immunotherapy to break through cancerNIHNational Cancer Institute2021 to 2025$5,025,838September 1, 2016August 31, 2030ZHAO, JEANreporter.nih.gov
Modeling Precision Interventions for Prostate Cancer ControlNIHNational Cancer Institute2021 to 2025$4,423,369June 15, 2025August 31, 2026ETZIONI, RUTH Dreporter.nih.gov
Urology Centers Program Interactions Core (U24)NIHNational Institute of Diabetes and Digestive and Kidney Diseases2021 to 2025$4,277,500September 17, 2020July 31, 2030PENNISTON, KRISTINA Lreporter.nih.gov
Bedside to bench resources for lower urinary tract researchNIHNational Institute of Diabetes and Digestive and Kidney Diseases2022 to 2025$4,039,744September 15, 2022May 31, 2027STRAND, DOUGLAS WILLIAMreporter.nih.gov
Modeling and analytics for cancer diagnostics: traversing the data-evidence divideNIHNational Cancer Institute2022 to 2025$3,872,365September 1, 2022August 31, 2029ETZIONI, RUTH Dreporter.nih.gov
GEMS: Genomic approach to connecting Elevated germline Mutation rates with male infertility and Somatic healthNIHEunice Kennedy Shriver National Institute of Child Health & Human Development2021 to 2025$3,803,952September 1, 2021May 31, 2027HOTALING, JAMESreporter.nih.gov
Genetic Predictors of Prostate Cancer SurvivalNIHNational Cancer Institute2021 to 2025$3,655,797January 15, 2021December 31, 2026KLEIN, ROBERT J.reporter.nih.gov
PSMA’s enzymatic activity as new target for Prostate Cancer diagnosis and therapyNIHNational Cancer Institute2021 to 2025$3,606,632July 1, 2021June 30, 2027GRIMM, JANreporter.nih.gov
Integrated radiomic and liquid biopsy monitoring in SWOG S1802: A phase 3 therapeutic trial for metastatic prostate cancerNIHNational Cancer Institute2021 to 2025$3,403,254February 9, 2021January 31, 2027GOLDKORN, AMIRreporter.nih.gov
Elucidation of the genetic mechanisms driving prostate tumorigenesis through integrative computational and functional approachesNIHNational Cancer Institute2021 to 2025$3,352,278March 2, 2021February 28, 2027FREEDMAN, MATTHEW Lreporter.nih.gov
Elucidating prostate cancer risk mechanisms through large-scale cistrome wide association studiesNIHNational Cancer Institute2022 to 2025$3,342,109September 1, 2022August 31, 2027FREEDMAN, MATTHEW Lreporter.nih.gov
Career Development in Pediatric and Medical OncologyNIHNational Cancer Institute2021 to 2025$3,314,336September 30, 1997August 31, 2026MESHINCHI, SOHEILreporter.nih.gov
Measuring Metabolic Activity in Prostate Cancer Bone Metastases Using Hyperpolarized 13C Pyruvate MRI for Improved Targeted Therapy MonitoringNIHNational Cancer Institute2021 to 2025$3,288,067December 1, 2020November 30, 2026VIGNERON, DANIEL Breporter.nih.gov
Hyperpolarized C-13 MRI Techniques to Monitor Radiation Therapy Response in Prostate Cancer PatientsNIHNational Cancer Institute2021 to 2025$3,266,535July 1, 2021June 30, 2027VIGNERON, DANIEL Breporter.nih.gov
3D High Resolution Magnetic Resonance Fingerprinting for Prostate CancerNIHNational Cancer Institute2021 to 2025$3,177,909August 1, 2021July 31, 2027JIANG, YUNreporter.nih.gov
Genomic profiling of single circulating tumor cells in the precision medicine of metastatic prostate cancerNIHNational Cancer Institute2021 to 2025$3,177,343July 8, 2021June 30, 2027YANG, HUSHANreporter.nih.gov
Prostate Cancer Biomarker and Imaging Validation Alliance: Emory University, University of Alabama Birmingham, and University of Texas SouthwesternNIHNational Cancer Institute2021 to 2025$3,170,165March 29, 2005June 30, 2028SANDA, MARTIN G.reporter.nih.gov
Enabling clinical tissue microstructure imaging as a diagnostic tool in wide-bore 3T MRINIHNational Institute of Biomedical Imaging and Bioengineering2023 to 2025$3,146,296September 1, 2023August 31, 2028FOO, THOMAS Kreporter.nih.gov
Transrectal Histotripsy for Focal Ablation of Prostate CancerNIHNational Cancer Institute2022 to 2025$3,132,373September 23, 2022August 31, 2027SCHADE, GEORGE Rreporter.nih.gov
A transdisciplinary approach for dissecting stem cell states in prostate cancerNIHNational Cancer Institute2021 to 2025$3,070,312September 20, 2021August 31, 2026RABADAN, RAULreporter.nih.gov
Multiethnic GWAS and TWAS to Inform Risk Prediction for Prostate CancerNIHNational Cancer Institute2021 to 2025$3,068,628May 1, 2025April 30, 2027HAIMAN, CHRISTOPHER ALANreporter.nih.gov
Identifying factors associated with prostate cancer progression and survival in African American men: The RESPOND CohortNIHNational Cancer Institute2024 to 2025$3,024,739July 23, 2024June 30, 2029HAIMAN, CHRISTOPHER ALANreporter.nih.gov
Prognostic and Predictive Digital Tissue Image Assay for Prostate CancerNIHNational Cancer Institute2022 to 2025$3,008,190September 5, 2022August 31, 2027MADABHUSHI, ANANTreporter.nih.gov
Computer Aided Diagnostic System for Prostate Cancer Detection Using Quantitative Multiparametric MRINIHNational Cancer Institute2021 to 2025$2,990,455September 23, 2021August 31, 2027METZGER, GREGORY JOHNreporter.nih.gov
Prostate Cancer Radio-Pathomics for Differentiating Clinically Significant DiseaseNIHNational Cancer Institute2021 to 2025$2,965,890March 1, 2021August 31, 2026LAVIOLETTE, PETER Sreporter.nih.gov
Molecular mechanisms underlying lineage plasticity in prostate cancerNIHNational Cancer Institute2021 to 2025$2,937,823April 1, 2025March 31, 2027BELTRAN, HIMISHAreporter.nih.gov
Early clinial trials for Angelica herbal supplements for prostate cancer interceptionNIHNational Cancer Institute2022 to 2025$2,932,860September 1, 2022August 31, 2027LU, JUNXUANreporter.nih.gov
Preventing invasive prostate cancerNIHNational Cancer Institute2023 to 2025$2,928,553September 19, 2023August 31, 2028BERGAN, RAYMOND C.reporter.nih.gov
Understanding and targeting epigentic regulation of immune evasion in prostate cancerNIHNational Cancer Institute2025$2,895,540August 1, 2025July 31, 2029CAI, LINGreporter.nih.gov
Targeting apoptotic cells to enhance radiotherapyNIHNational Cancer Institute2022 to 2025$2,817,814September 22, 2022August 31, 2027RAO, JIANGHONGreporter.nih.gov
Metabolomic Signatures of Urologic Chronic Pelvic Pain SyndromeNIHNational Institute of Diabetes and Digestive and Kidney Diseases2021 to 2025$2,812,460July 15, 2021April 30, 2027HENDERSON, JEFFREY Preporter.nih.gov
Uncovering causal protein markers to improve prostate cancer etiology understanding and risk prediction in Africans and EuropeansNIHNational Cancer Institute2022 to 2025$2,762,045July 1, 2022June 30, 2027WU, LANGreporter.nih.gov
High throughput infrastructure for reaction screening and bioassaysNIHNational Center for Advancing Translational Sciences2024 to 2025$2,752,647June 29, 2022May 31, 2027COOKS, ROBERT GRAHAMreporter.nih.gov
Investigating the mechanisms of driver genes associated with ancestry and aggressiveness in prostate cancerNIHNational Cancer Institute2021 to 2025$2,739,005May 10, 2021April 30, 2027CAMPBELL, JOSHUA Dreporter.nih.gov
Minimizing salivary gland and renal toxicity arising from PSMA-targeted alpha therapyNIHNational Cancer Institute2022 to 2025$2,733,165May 1, 2022April 30, 2027PILLARSETTY, NAGAVARAKISHOREreporter.nih.gov
Systemic RNA Delivery to TumorsNIHNational Cancer Institute2021 to 2025$2,731,905December 21, 2015June 30, 2027SHI, JINJUNreporter.nih.gov
Metastasis of PTEN Mutant Prostate CancerNIHNational Cancer Institute2022 to 2025$2,701,454September 1, 2022August 31, 2027TROTMAN, LLOYD Creporter.nih.gov
Understanding how T cell intrinsic androgen receptor activity influences cell differentiation and dysfunctionNIHNational Cancer Institute2021 to 2025$2,692,281July 6, 2021June 30, 2026MORAN, AMY Ereporter.nih.gov
Plk1 as a prognostic biomarker for prostate cancerNIHNational Cancer Institute2021 to 2025$2,686,273July 1, 2021June 30, 2026LIU, XIAOQIreporter.nih.gov
Clinical Qualification of Imaging and Fluid-Based Tumor Monitoring Biomarkers for Metastatic Castration Resistant Prostate CancerNIHNational Cancer Institute2023 to 2025$2,654,692July 1, 2020June 30, 2026SCHWARTZ, LAWRENCE Hreporter.nih.gov
Disrupting the Prostate Tumor Microenvironment in African American Men to Promote Response to Immuno-Modulatory TherapyNIHNational Cancer Institute2022 to 2025$2,642,372September 1, 2022August 31, 2027YAMOAH, KOSJreporter.nih.gov
Targeting the cGAS/STING Pathway to Overcome Resistance to Immune Checkpoint Inhibitors in PTEN-deficient Prostate CancerNIHNational Cancer Institute2022 to 2025$2,630,502September 20, 2022August 31, 2027PATNAIK, AKASHreporter.nih.gov
Enhancing the Efficacy of Docetaxel in Prostate CancerNIHNational Cancer Institute2022 to 2025$2,590,555July 13, 2022June 30, 2027BALK, STEVEN P.reporter.nih.gov
Identifying Cancer Recurrence with Novel Data Linkages with a Cancer RegistryNIHNational Cancer Institute2022 to 2025$2,585,593August 1, 2022July 31, 2027DOHERTY, JENNIFER ANNEreporter.nih.gov
Molecular Biomarkers of Long-Term Response to Androgen Deprivation Therapy and Radiation in Prostate CancerNIHNational Cancer Institute2022 to 2025$2,551,647January 1, 2022December 31, 2026MAHER, CHRISTOPHER Areporter.nih.gov
Clinical genomic predictive model of first line androgen receptor inhibitor therapy outcomes in men with mCRPCNIHNational Cancer Institute2022 to 2025$2,528,918September 16, 2020December 31, 2026HALABI, SUSANreporter.nih.gov
High-dose Vitamin D Supplementation for ADT-Induced Bone Loss in Older Prostate Cancer PatientsNIHNational Cancer Institute2022 to 2025$2,508,029December 17, 2021November 30, 2026PEPPONE, LUKE JOSEPHreporter.nih.gov
ZC3H4 Driven Prostate Tissue Remodeling Triggered by Maladaptive Metabolic and Signaling PathwaysNIHNational Institute of Diabetes and Digestive and Kidney Diseases2025$2,482,346September 15, 2025August 31, 2029PASCAL, LAURA ELLENreporter.nih.gov
Preclinical analyses of advanced prostate cancer in genetically-engineered miceNIHNational Cancer Institute2021 to 2025$2,462,511August 6, 2013January 31, 2028ABATE-SHEN, CORYreporter.nih.gov
Multichannel Fluorescence Guided Surgery Tools Enabling Simultaneous Cancer Margin and Nerve Visualization in ProstatectomyNIHNational Cancer Institute2022 to 2025$2,453,547May 10, 2022April 30, 2027GIBBS, SUMMER LYNNEreporter.nih.gov
Elucidation of the mechanisms by which cells recognize and respond to different levels of androgensNIHNational Cancer Institute2022 to 2025$2,436,399September 1, 2022July 31, 2027MCDONNELL, DONALD Preporter.nih.gov
Ionization Detail - Biologically based treatment planning for particle therapy beyond LET-RBENIHNational Cancer Institute2022 to 2025$2,434,477September 1, 2022August 31, 2027FADDEGON, BRUCEreporter.nih.gov
Enhancing the efficacy of androgen signaling inhibitors in prostate cancerNIHNational Cancer Institute2021 to 2025$2,422,948July 1, 2021June 30, 2026LIU, XIAOQIreporter.nih.gov
High resolution transcriptome and gene regulatory mapping of human ureter and bladder across the lifespanNIHNational Institute of Diabetes and Digestive and Kidney Diseases2021 to 2025$2,415,000September 30, 2021July 31, 2027WESSELY, OLIVERreporter.nih.gov
Precision Prostate Cancer Screening with Genetically Adjusted Prostate-Specific Antigen LevelsNIHNational Cancer Institute2021 to 2025$2,414,500April 1, 2020March 31, 2030WITTE, JOHN S.reporter.nih.gov
Pelvic fascia spARing radical prostatectomy TrIAL (PARTIAL)NIHNational Cancer Institute2022 to 2025$2,411,833February 4, 2022July 31, 2028HU, JIMreporter.nih.gov
PSMA-PET to Guide Prostatectomy: Can PSMA-PET Appropriately Modify Surgery, Reduce Nerve Damage and Optimize Quality-of-Life?NIHNational Cancer Institute2022 to 2025$2,408,587March 1, 2022February 28, 2027BAHLER, CLINTON DAVIDreporter.nih.gov
Microfluidic isolation and molecular analysis of circulating tumor cells for the study of neuroendocrine transdifferentiation in prostate cancerNIHNational Cancer Institute2022 to 2025$2,406,187April 1, 2022March 31, 2027TONER, MEHMETreporter.nih.gov
Targeting Castration Resistant Prostate Cancer via Potent Inhibition of Signaling LipidsNIHNational Cancer Institute2022 to 2025$2,404,562September 1, 2022August 31, 2027KAOCHAR, SALMAreporter.nih.gov
Development of an Innovative PSMA-Targeted Small Molecule Prodrug for Prostate CancerNIHNational Cancer Institute2024 to 2025$2,399,998September 2, 2024August 31, 2026LANGTON-WEBSTER, BEATRICEreporter.nih.gov
Noninvasive assessment of detrusor pressure and dysfunctionNIHNational Institute of Diabetes and Digestive and Kidney Diseases2022 to 2025$2,382,351February 15, 2022December 31, 2026FATEMI, MOSTAFAreporter.nih.gov
Ultra-Low Count Quantitative SPECT for Alpha-Particle TherapiesNIHNational Institute of Biomedical Imaging and Bioengineering2022 to 2025$2,381,642September 30, 2022June 30, 2027JHA, ABHINAV Kreporter.nih.gov
Functional Characterization and Development of Therapeutic Paradigms for DNA Damage Repair (DDR)-deficient Lethal Prostate CancerNIHNational Cancer Institute2023 to 2025$2,380,224April 1, 2023March 31, 2028CHAKRABORTY, GOUTAMreporter.nih.gov
Molecular imaging of novel PARP inhibitor nanomedicine deliveryNIHNational Cancer Institute2022 to 2025$2,377,967August 12, 2022July 31, 2027VANBROCKLIN, HENRY F.reporter.nih.gov
MELT: Modulation of PSMA Expression for Lutetium TherapyNIHNational Cancer Institute2021 to 2025$2,363,818July 1, 2019June 30, 2026HOPE, THOMAS Areporter.nih.gov
NOT-CA-24-111 Improving Strategies for Cancer Reduction through Early-detection and ENgagement (I-SCREEN)NIHNational Cancer Institute2024 to 2025$2,357,813February 14, 2024December 31, 2027COOK, LINDA Sreporter.nih.gov
Bioengineered Prostate-on Chip: Mechanisms of Stromal Dysregulation in Prostate CancerNIHNational Cancer Institute2021 to 2025$2,349,240April 7, 2021March 31, 2027MIRANTI, CYNTHIA Kreporter.nih.gov
Novel therapeutics dual targeting intracrine androgen synthesis and AR for advanced prostate cancerNIHNational Cancer Institute2022 to 2025$2,339,824April 1, 2022March 31, 2027GAO, ALLEN C.reporter.nih.gov
Real time fine needle assessment of architectural heterogeneity in prostate cancerNIHNational Cancer Institute2021 to 2025$2,327,219January 18, 2019December 31, 2025XU, GUANreporter.nih.gov
Molecular mechanisms of prostate cancer metastasisNIHNational Cancer Institute2021 to 2025$2,326,612January 1, 2015June 30, 2027ABATE-SHEN, CORYreporter.nih.gov
Role of ETS factors in specifying prostate luminal cell identity and androgen receptor dependenceNIHNational Cancer Institute2021 to 2025$2,315,488April 1, 2015August 31, 2025SAWYERS, CHARLES L.reporter.nih.gov
Interplay between tumor and microenvironment in bone metastasisNIHNational Cancer Institute2021 to 2025$2,312,393April 1, 2021March 31, 2026FISHER, PAUL Breporter.nih.gov
Increasing nerve-sparing radical prostatectomy rates using intraoperative nonlinear microscopyNIHNational Cancer Institute2021 to 2025$2,308,361February 5, 2021January 31, 2027FUJIMOTO, JAMES Greporter.nih.gov
Using Prostate Health Index and MRI in Combination for Cost-effectively Detecting High-Grade Prostate CancerNIHNational Cancer Institute2021 to 2025$2,307,356September 14, 2020June 30, 2026MURPHY, ADAM Breporter.nih.gov
Super Resolution for Improved Multislice Prostate MRINIHNational Institute of Biomedical Imaging and Bioengineering2022 to 2025$2,303,815July 10, 2022May 31, 2026RIEDERER, STEPHEN Jreporter.nih.gov
Rad-pathomic deep learning models to assist radiologists in differentiating aggressive from indolent prostate cancer on MRINIHNational Cancer Institute2022 to 2025$2,302,630January 12, 2022December 31, 2026RUSU, MIRABELAreporter.nih.gov
HFH-MSU CSRN ACCrual Enrollment and Screening SiteNIHNational Cancer Institute2024 to 2025$2,289,116March 7, 2025December 31, 2027NESLUND-DUDAS, CHRISTINE MARIEreporter.nih.gov
DeepSRH: Transforming Molecular Cancer Screening with Stimulated Raman Histology and Deep Neural NetworksNIHNational Cancer Institute2025$2,284,054September 1, 2025August 31, 2029HOLLON, TODD CHARLESreporter.nih.gov
Intermittent Fasting using a Fasting-Mimetic Diet to Improve Prostate Cancer Control and Metabolic OutcomesNIHNational Cancer Institute2023 to 2025$2,274,110July 1, 2023June 30, 2028FREEDLAND, STEPHEN JAYreporter.nih.gov
Aligning financial incentives to promote rational use of active surveillance for prostate cancerNIHNational Cancer Institute2022 to 2025$2,252,166April 1, 2022March 31, 2027SHAHINIAN, VAHAKN Breporter.nih.gov
Digital Multiplexed Analysis of Circulating Nucleic Acids in Small-Volume Blood SpecimensNIHNational Institute of Biomedical Imaging and Bioengineering2022 to 2025$2,239,028August 15, 2022May 31, 2026SMITH, ANDREW MICHAELreporter.nih.gov
Development of Novel Targeted Therapeutic Agents for Castration Resistant Prostate CancerNIHNational Cancer Institute2022 to 2025$2,194,673June 3, 2022May 31, 2027OYELERE, ADEGBOYEGAreporter.nih.gov
Hsp60 Regulation of Prostate Cancer ProgressionNIHNational Cancer Institute2021 to 2025$2,185,351September 1, 2021August 31, 2027CHANDRA, DHYANreporter.nih.gov
Lipoteichoic acid mediated modulation of chronic painNIHNational Institute of Diabetes and Digestive and Kidney Diseases2022 to 2025$2,182,686August 1, 2016June 30, 2027THUMBIKAT, PRAVEENreporter.nih.gov
Structure, function, and application of novel antagonists of the intrinsically disordered androgen receptor amino-terminal domain as imaging agents and therapeuticsNIHNational Cancer Institute2021 to 2025$2,182,643July 13, 2021June 30, 2027SADAR, MARIANNE Dreporter.nih.gov
Targeting AR and AR-Variants in Castration-Resistant Prostate CancerNIHNational Cancer Institute2021 to 2025$2,175,178February 1, 2021January 31, 2027DAMODARAN, CHENDILreporter.nih.gov
Diffusion Histology Imaging: A Clinical Tool to Non-Invasively Diagnose and Manage Prostate CancerNIHNational Cancer Institute2022 to 2025$2,170,868January 1, 2022December 31, 2026IPPOLITO, JOSEPH EDWARDreporter.nih.gov
Mechanisms of Prostate Cancer MetastasisNIHNational Cancer Institute2021 to 2025$2,155,774September 17, 2021August 31, 2026FREEMAN, MICHAEL R.reporter.nih.gov
A non-canonical role for EZH2 in rRNA methtlationNIHNational Cancer Institute2021 to 2025$2,146,235July 15, 2021June 30, 2026CAO, QIreporter.nih.gov
Leveraging deep learning for markerless motion management in radiation therapyNIHNational Cancer Institute2021 to 2025$2,135,070April 1, 2021March 31, 2026XING, LEIreporter.nih.gov
A First-in-Class FAP-activated Protoxin to disrupt the Tumor-Stroma Parasitic Cycle fueling lethal Prostate Cancer ProgressionNIHNational Cancer Institute2021 to 2025$2,103,278January 1, 2021December 31, 2025BRENNEN, WILLIAM NATHANIELreporter.nih.gov
An AI-enabled Digital Pathology Platform for Multi-Cancer Diagnosis, Prognosis and Prediction of Therapeutic BenefitNIHNational Cancer Institute2022 to 2025$2,081,138September 5, 2022August 31, 2027MADABHUSHI, ANANTreporter.nih.gov
Preserving Erectile Function by Quantifying the Nerve-Sparing step of the Robotic ProstatectomyNIHNational Cancer Institute2023 to 2025$2,077,876July 7, 2022June 30, 2027HUNG, ANDREWreporter.nih.gov
Nitric Oxide-Soluble Guanylate Cyclase Pathway as a Target for Male Bladder Outlet Obstruction and Lower Urinary Tract Symptoms in AgingNIHNational Institute of Diabetes and Digestive and Kidney Diseases2023 to 2025$2,068,975August 19, 2023June 30, 2027KANAI, ANTHONY JOHNreporter.nih.gov
Leveraging whole-exome sequence data from diverse biobanks and cohorts to study rare coding variation in prostate cancerNIHNational Cancer Institute2023 to 2025$2,067,626September 20, 2023August 31, 2028HAIMAN, CHRISTOPHER ALANreporter.nih.gov
Optimizing Treatment of Prostate Cancer in Men living with HIVNIHNational Cancer Institute2023 to 2025$2,059,152August 1, 2023June 30, 2028SIGEL, KEITH MAGNUSreporter.nih.gov
A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (mCRPC)NIHNational Cancer Institute2023 to 2025$2,048,902July 7, 2023June 30, 2027SCHULER, AARON Dreporter.nih.gov
3D Spatial Biology of Prostate Cancer Biopsies For Earlier Identification of High Risk PatientsNIHNational Cancer Institute2024 to 2025$2,045,816September 5, 2020June 30, 2027REDER, NICHOLASreporter.nih.gov
Intensive cholesterol-lowering intervention and anti-tumor immunity modeled in prostate cancerNIHNational Cancer Institute2023 to 2025$2,041,405September 21, 2023August 31, 2028KIM, HYUNG Lreporter.nih.gov
Creatine supplementation and resistance training to preserve muscle mass and attenuate cancer progression: A double-blind randomized controlled trialNIHNational Cancer Institute2023 to 2025$2,036,734September 1, 2023August 31, 2028COLETTA, ADRIANAreporter.nih.gov
Lineage Plasticity, due to Disruption of MnSOD Biology, drives resistance to Ionizing Radiation / Androgen Deprivation TherapyNIHNational Cancer Institute2021 to 2025$2,021,205April 9, 2021March 31, 2027GIUS, DAVIDreporter.nih.gov
Single-Cell Analysis of the Noncoding Genome in Human Diseases and EvolutionNIHNational Institute of General Medical Sciences2021 to 2025$2,018,750August 13, 2021June 30, 2027LI, JINGJINGreporter.nih.gov
Androgen receptor pathway inhibition through targeting PARP-2 in castration-resistant prostate cancerNIHNational Cancer Institute2021 to 2025$2,010,462July 1, 2021June 30, 2026JIA, LIreporter.nih.gov
Specificity of regulatory T cell suppression during infectionNIHNational Institute of Allergy and Infectious Diseases2021 to 2025$2,009,680May 1, 2021April 30, 2026SAVAGE, PETER AIDANreporter.nih.gov
Toxicology (IND-enabling) studies for a novel nerve imaging agent for prostate cancerNIHNational Cancer Institute2024 to 2025$1,996,496September 6, 2024August 31, 2026KAHL, STEPHEN Breporter.nih.gov
Characterizing the binding mechanisms of castration-resistant prostate cancer therapeutics to the intrinsically disordered N-terminal domain of the androgen receptorNIHNational Institute of General Medical Sciences2021 to 2025$1,979,921September 15, 2021June 30, 2026ROBUSTELLI, PAULreporter.nih.gov
Molecular regulation and expression of Trop-2 in advanced prostate cancer: Identifying optimal therapeutic nichesNIHNational Cancer Institute2023 to 2025$1,972,155July 1, 2023June 30, 2028LANG, JOSHUAreporter.nih.gov
Targeting Non-Canonical STING Signaling to Treat SPOP Mutant Castration-Resistant Prostate CancerNIHNational Cancer Institute2023 to 2025$1,971,553September 19, 2023August 31, 2028THOMPSON, TIMOTHY CHARLESreporter.nih.gov
Prostate Cancer Vulnerabilities to BH3 Mimetic DrugsNIHNational Cancer Institute2021 to 2025$1,965,536June 1, 2021May 31, 2026BALK, STEVEN P.reporter.nih.gov
Systematic evaluation of toxicity and therapeutic efficacy in CD46 directed radioligand therapyNIHNational Cancer Institute2023 to 2025$1,959,827May 1, 2023April 30, 2028FLAVELL, ROBERT RICHARDreporter.nih.gov
A novel strategy to overcome drug resistance in cancerNIHNational Cancer Institute2021 to 2025$1,956,732March 1, 2021February 28, 2027EDINGER, AIMEE Lreporter.nih.gov
Germline Determinants of Prostate Cancer EvolutionNIHNational Cancer Institute2023 to 2025$1,954,844April 1, 2023March 31, 2028SPELLMAN, PAUL T.reporter.nih.gov
Optimizing prostate cancer care: integrating risks, benefits, and patient experiences in the new era of molecular imagingNIHNational Cancer Institute2023 to 2025$1,950,868September 13, 2023August 31, 2028LEAPMAN, MICHAEL STUARTreporter.nih.gov
Interleukin-1beta and AR-negative tumor cells in metastatic castrate-resistant prostate cancerNIHNational Cancer Institute2022 to 2025$1,945,498September 1, 2022August 31, 2027FATATIS, ALESSANDROreporter.nih.gov
Targeting the colchicine binding site in tubulin for cancer therapyNIHNational Cancer Institute2021 to 2025$1,935,287January 1, 2011December 31, 2026LI, WEIreporter.nih.gov
Targeting the microtubule cytoskeleton to promote cavernous nerve regeneration and erectile function after injuryNIHNational Institute of Diabetes and Digestive and Kidney Diseases2023 to 2025$1,928,183September 1, 2023June 30, 2028DAVIES, KELVIN Preporter.nih.gov
A Digital Twin for Designing Bladder Treatment informed by Bladder Outlet Obstruction Mechanobiology (BOOM)NIHNational Institute of Diabetes and Digestive and Kidney Diseases2023 to 2025$1,925,422August 11, 2023July 31, 2028ROBERTSON, ANNE MARIEreporter.nih.gov
Androgen Signaling in CaP with loss of MAP3K7 and CHD1NIHNational Cancer Institute2021 to 2025$1,924,438July 1, 2021June 30, 2026CRAMER, SCOTT Dreporter.nih.gov
Polygenic risk stratification combined with mpMRI to identify clinically relevant prostate cancerNIHNational Cancer Institute2023 to 2025$1,922,720April 12, 2023March 31, 2028KIBEL, ADAM Sreporter.nih.gov
"DNMT and TET1 reprogramming as a targetable mechanism of resistance in advanced prostate cancer"NIHNational Cancer Institute2023 to 2025$1,921,654June 1, 2023May 31, 2028RICKMAN, DAVID S.reporter.nih.gov
Drug Development of Skp2 PROTACs in CancerNIHNational Cancer Institute2023 to 2025$1,912,388May 31, 2023April 30, 2028LI, HONG-YUreporter.nih.gov
AR Gene Rearrangements and AR Signaling in Prostate CancerNIHNational Cancer Institute2021 to 2025$1,909,771April 1, 2013March 31, 2028DEHM, SCOTT M.reporter.nih.gov
Ligand-mediated, vehicle-free delivery of small RNAsNIHNational Cancer Institute2021 to 2025$1,908,192April 1, 2018August 31, 2028KASINSKI, ANDREA Lreporter.nih.gov
Deciphering Mechanisms of Tumor-Stromal Interactions in Prostate CancerNIHNational Cancer Institute2021 to 2025$1,908,093May 1, 2021April 30, 2027WU, BOYANGreporter.nih.gov
Targeting Mitochondrial Redox Capacity to Overcome Cancer Subtype that Regrowth After RadiationNIHNational Cancer Institute2021 to 2025$1,906,181April 1, 2021March 31, 2027CHAISWING, LUKSANAreporter.nih.gov
Mechanisms of metabolic stress-induced transcriptional regulation in prostate cancerNIHNational Cancer Institute2021 to 2025$1,900,860April 1, 2021March 31, 2027DASGUPTA, SUBHAMOYreporter.nih.gov
"Novel Mouse Models for Quantitative Understanding of Baseline and Therapy-Driven Evolution of Prostate Cancer Metastasis"NIHNational Cancer Institute2023 to 2025$1,899,979April 1, 2023March 31, 2028NOWAK, DAWID GRZEGORZreporter.nih.gov
Effects of TNF Blockade on Human BPH/LUTSNIHNational Institute of Diabetes and Digestive and Kidney Diseases2023 to 2025$1,899,179August 15, 2023May 31, 2028HAYWARD, SIMON Wreporter.nih.gov
Discriminatory Mechanisms in Early-Onset and Lethal Prostate CancerNIHNational Cancer Institute2021 to 2025$1,894,111August 13, 2021July 31, 2026COHN, BARBARA Areporter.nih.gov
Functional Analysis of Structure Specific Nucleases in Genome Stability and CancersNIHNational Cancer Institute2021 to 2025$1,887,170September 20, 2016August 31, 2026ZHENG, LIreporter.nih.gov
Racially-associated MRI analysis and modeling for predicting aggressive prostate cancerNIHNational Cancer Institute2023 to 2025$1,884,679September 15, 2023August 31, 2028SUNG, KYUNG HYUNreporter.nih.gov
Inside-Out Nonlinear Gradients to Improve Diffusion MRINIHNational Cancer Institute2021 to 2025$1,881,297July 6, 2021September 30, 2026GALIANA, GIGIreporter.nih.gov
Effects of Arginine Depletion Combined with Platinum-Taxane Chemotherapy in Aggressive Variant Prostate Cancers (AVPC)NIHNational Cancer Institute2023 to 2025$1,877,904September 21, 2023August 31, 2028APARICIO, ANAreporter.nih.gov
Statistical methods for genomic analysis of heterogeneous tumorsNIHNational Cancer Institute2022 to 2025$1,872,847July 8, 2022June 30, 2027WANG, WENYIreporter.nih.gov
Therapeutic targeting Wnt5A signaling for advanced prostate cancerNIHNational Cancer Institute2021 to 2025$1,872,645December 1, 2020November 30, 2026GAO, ALLEN C.reporter.nih.gov
Targeting the Plk1/Pdcd4/mTORC2 Signaling to Treat Castration-Resistant Prostate CancerNIHNational Cancer Institute2023 to 2025$1,867,088July 1, 2023June 30, 2028LIU, XIAOQIreporter.nih.gov
Physician dispensing of oral specialty drugs for advanced prostate cancer and its implications for patientsNIHNational Cancer Institute2023 to 2025$1,856,603February 1, 2023August 31, 2028HOLLENBECK, BRENT K.reporter.nih.gov
Development of Next-Generation Blood-to-barcode (B2B) chip for In Vivo CRISPR-Based Discovery of Metastasis RegulatorsNIHNational Cancer Institute2023 to 2025$1,846,447February 7, 2023January 31, 2028KELLEY, SHANA Oreporter.nih.gov
Addressing Circulation of Guideline-Discordant Information to Promote Optimal Prostate Cancer CareNIHNational Cancer Institute2023 to 2025$1,837,936February 7, 2023January 31, 2028LOEB, STACYreporter.nih.gov
High-throughput Clinical Hyperpolarized 13C MRINIHOffice of the Director, National Institutes of Health2025$1,835,840August 1, 2025July 1, 2027TSAI, LEO LEEreporter.nih.gov
Elevated homocysteine in African American Prostate Cancer: Association with Diet and Dietary practices, evaluating its biomarker potential, and characterizing its tumor promoting functionNIHNational Cancer Institute2022 to 2025$1,824,802April 1, 2022March 31, 2027SREEKUMAR, ARUNreporter.nih.gov
Identifying lethal prostate cancer at diagnosis with advanced proteoglycomic, radiomic, and genomic approachesNIHNational Cancer Institute2023 to 2025$1,823,701July 7, 2023June 30, 2028IPPOLITO, JOSEPH EDWARDreporter.nih.gov
Targeting m6A RNA epigenetics in treatment-emergent neuroendocrine prostate cancerNIHNational Cancer Institute2021 to 2025$1,819,525June 4, 2021November 30, 2026SONG, MIN SUPreporter.nih.gov
Development of Methods for a Simplified and Reliable Prostate Cancer MRI ExamNIHNational Cancer Institute2021 to 2025$1,799,393June 1, 2020November 30, 2026MAIER, STEPHAN Ereporter.nih.gov
Adaptive Percutaneous Prostate Interventions using Sensorized NeedleNIHNational Cancer Institute2021 to 2025$1,799,242August 1, 2019February 29, 2028TOKUDA, JUNICHIreporter.nih.gov
Defining the role of isoprenylated xanthones from the mangosteen for enhancing degradation of full length and variant forms of androgen receptor in prostate cancerNIHNational Cancer Institute2021 to 2025$1,796,578January 1, 2019April 30, 2027JOHNSON, JEREMY JAMESreporter.nih.gov
Stromal Foxf2 suppresses prostate cancer progressionNIHNational Cancer Institute2022 to 2025$1,790,773July 1, 2022May 31, 2027XIN, LIreporter.nih.gov
Tailored prostate cancer screening: addressing USPSTF priority research gaps in a racially-diverse study populationNIHNational Cancer Institute2023 to 2025$1,787,388August 1, 2023July 31, 2028LANGSTON, MARVIN EPOLIANreporter.nih.gov
Modulating HSP70/STUB1 machinery in therapy-resistant prostate cancerNIHNational Cancer Institute2021 to 2025$1,783,175September 1, 2021August 31, 2026LIU, CHENGFEIreporter.nih.gov
Dissecting the Role of Proteostasis in Anti-Androgen Resistant Prostate CancerNIHNational Cancer Institute2021 to 2025$1,770,550July 1, 2021June 30, 2026LIU, CHENGFEIreporter.nih.gov
A novel AR degrader in castrate-resistant prostate cancerNIHNational Cancer Institute2023 to 2025$1,765,881August 15, 2023June 30, 2028KIM, HYEONG-REH CHOIreporter.nih.gov
Evaluating prostate cancer phenotype and genotype classification from circulating tumor DNA as biomarkers for predicting treatment outcomesNIHNational Cancer Institute2023 to 2025$1,755,220September 19, 2023August 31, 2028HA, GAVINreporter.nih.gov
Ethical Multimodal fusion Artificial Intelligence platform (EMAP) to bridge the gap between imaging modalities: Application to prostate cancer diagnosis.NIHOffice of the Director, National Institutes of Health2025$1,753,477September 15, 2025September 14, 2026RUSU, MIRABELAreporter.nih.gov
Novel Therapeutic Strategies to Co-Target Undifferentiated Prostate Cancer (PCa) Stem Cells and Bulk PCa CellsNIHNational Cancer Institute2021 to 2025$1,753,253June 1, 2019March 31, 2030TANG, DEAN G.reporter.nih.gov
Targeting Polo-Like Kinase 1 in Prostate Cancer to Enhance Therapeutic EfficacyNIHNational Cancer Institute2022 to 2025$1,749,738July 1, 2022June 30, 2027LI, ZHIGUOreporter.nih.gov
Targeting allosteric scaffolding functions of Aurora kinase A in cancerNIHNational Cancer Institute2021 to 2025$1,740,140April 1, 2021March 31, 2027LEVINSON, NICHOLAS MARKreporter.nih.gov
A dyadic exercise approach to prevent declines in physical and mental health in couples during radiation treatment for cancer: a hybrid type I efficacy-implementation trialNIHNational Cancer Institute2023 to 2025$1,737,544July 1, 2023June 30, 2028WINTERS-STONE, KERRI Mreporter.nih.gov
Novel Approaches Targeting B7-H3 in Castration-resistant Prostate CancerNIHNational Cancer Institute2023 to 2025$1,734,793January 1, 2023December 31, 2027ZHAO, DIreporter.nih.gov
RET Regulation and Targeting in Neuroendocrine Prostate CancerNIHNational Cancer Institute2022 to 2025$1,732,079May 1, 2022April 30, 2027DRAKE, JUSTIN MICHAELreporter.nih.gov
Leveraging PMN immune response to overcome ADT resistance in bone metastatic prostate cancerNIHNational Cancer Institute2022 to 2025$1,731,077September 1, 2022August 31, 2027MATHEW, GRINUreporter.nih.gov
MAOA and AR Reciprocal Crosstalk in Prostate CancerNIHNational Cancer Institute2021 to 2025$1,725,441January 1, 2019December 31, 2025WU, BOYANGreporter.nih.gov
Parp Function in Prostate CancerNIHNational Cancer Institute2021 to 2025$1,722,423March 1, 2017February 29, 2028PASCHAL, BRYCEreporter.nih.gov
Improved Detection of Prostate Cancer with Nanoparticle-based Ultrasound Contrast Agents Targeted to PSMANIHNational Institute of Biomedical Imaging and Bioengineering2021 to 2025$1,708,848December 15, 2017January 31, 2028EXNER, AGATA Areporter.nih.gov
The Impact of Aging on Prostate Cancer with Age-Related Disruption of Th17/Treg AxisNIHNational Cancer Institute2021 to 2025$1,707,208January 1, 2021December 31, 2026ZHANG, QIUYANGreporter.nih.gov
Internet-Based Lifestyle Intervention to Eradicate Obese Frailty in Prostate Cancer Survivors (iLIVE)NIHNational Cancer Institute2023 to 2025$1,705,585June 22, 2023May 31, 2028WINTERS-STONE, KERRI Mreporter.nih.gov
Determine the Microphthalmia Transcription Factor (MITF)-regulated cell rewiring mechanisms in lethal prostate cancerNIHNational Cancer Institute2021 to 2025$1,690,924February 3, 2022June 30, 2027DOMINGO-DOMENECH, JOSEP MARIAreporter.nih.gov
Sacral neuromodulation for the management of chronic pelvic painNIHNational Institute of Diabetes and Digestive and Kidney Diseases2023 to 2025$1,689,002September 20, 2023July 31, 2028PETERS, KENNETH Mreporter.nih.gov
Multidimensional analyses to improve PSMA-RPT efficacy in mCRPCNIHNational Cancer Institute2023 to 2025$1,679,715July 12, 2023March 31, 2028CZERNIN, JOHANNESreporter.nih.gov
Stromal senescence in lethal prostate cancer: a novel target for prognosis and therapyNIHNational Cancer Institute2021 to 2025$1,668,272January 1, 2021December 31, 2025PLATZ, ELIZABETH A.reporter.nih.gov
The telomere biomarker as a tool to inform decision-making for aggressive salvage therapy in men with rising PSA post prostatectomyNIHNational Cancer Institute2023 to 2025$1,663,456August 22, 2023July 31, 2027MEEKER, ALAN KEITHreporter.nih.gov
Mechanisms of contractile dysfunction in the obstructed bladder: Role of desmin and vimentinNIHNational Institute of Diabetes and Digestive and Kidney Diseases2022 to 2025$1,656,768September 15, 2022May 31, 2027ETTICKAN, BOOPATHIreporter.nih.gov
Targeting chemoresistant prostate cancer with novel EED inhibitorsNIHNational Cancer Institute2022 to 2025$1,655,250April 1, 2022March 31, 2028WU, DAQINGreporter.nih.gov
Targeting Ferroptosis in Lethal RB1 Deficient Prostate CancerNIHNational Cancer Institute2022 to 2025$1,651,150April 1, 2022March 31, 2027CHEN, MINGreporter.nih.gov
Engineering Large Chromosomal Deletions in Mice to Advance Precision OncologyNIHNational Cancer Institute2022 to 2025$1,637,004March 1, 2022February 28, 2027CHEN, MINGreporter.nih.gov
Therapeutic targeting of master regulators in non-canonical AR driven advanced lethal prostate cancersNIHNational Cancer Institute2023 to 2025$1,633,514August 10, 2023July 31, 2028ADELAIYE-OGALA, REMIreporter.nih.gov
Role of the CD44/Hyaluronan axis in mesenchymal prostate cancerNIHNational Cancer Institute2023 to 2025$1,621,817August 1, 2023July 31, 2028DIAZ MECO CONDE, MARIA TERESAreporter.nih.gov
Influence of intra-individual variability in serial screening samples on clinical decision-making for risk stratification and biopsy by a single PSA and additional markersNIHNational Cancer Institute2022 to 2025$1,612,380September 22, 2022August 31, 2027EASTHAM, JAMES Areporter.nih.gov
Improving chemotherapy of castration-resistant prostate cancer.NIHNational Cancer Institute2021 to 2025$1,603,204August 10, 2016June 30, 2026LIU, XIAOQIreporter.nih.gov
A novel determinant of prostate cancer growthNIHNational Cancer Institute2021 to 2025$1,596,877April 1, 2021March 31, 2026HEEMERS, HANNELOREreporter.nih.gov
Developing Functional Human Cell Models to Study Initiation and Progression of Prostate Cancer between AA and EA menNIHNational Cancer Institute2023 to 2025$1,586,636May 1, 2023April 30, 2028LIU, XUEFENGreporter.nih.gov
Targeting Vulnerabilities Exposed by Cancer Treatment-Induced Lineage PlasticityNIHNational Cancer Institute2022 to 2025$1,582,219July 1, 2022June 30, 2027NELSON, PETER Sreporter.nih.gov
Differential activation of the triacylglycerol pathway in lipofibroblasts induces neurogenesis associated with prostate cancer progressionNIHNational Cancer Institute2025$1,575,170September 12, 2025July 31, 2029FRANCO CORONEL, OMARreporter.nih.gov
Examining the Relationship between Residential History at Midlife and Prostate Cancer OutcomesNIHNational Institute on Minority Health and Health Disparities2023 to 2025$1,561,820August 16, 2023February 29, 2028ZEIGLER-JOHNSON, CHARNITA M.reporter.nih.gov
Robot-Assisted Personalized Prostate BiopsyNIHNational Cancer Institute2021 to 2025$1,543,611April 1, 2021March 31, 2027STOIANOVICI, DANreporter.nih.gov
Hormone signaling and translation control in advanced prostate cancerNIHNational Cancer Institute2022 to 2025$1,542,779December 1, 2023November 30, 2025HSIEH, ANDREW CALEBreporter.nih.gov
Developing A Novel Combinatorial Therapy for Lethal Neuroendocrine Prostate CancerNIHNational Cancer Institute2022 to 2025$1,535,622August 1, 2022July 31, 2027CHEN, MINGreporter.nih.gov
Targeting MED31-driven transcription recycling in lethal prostate cancerNIHNational Cancer Institute2023 to 2025$1,523,960July 1, 2023June 30, 2028HE, YIPINGreporter.nih.gov
Role of E-Cadherin Down-Regulation in Prostatic Inflammation and Lower Urinary Tract DysfunctionNIHNational Institute of Diabetes and Digestive and Kidney Diseases2023 to 2025$1,523,140March 1, 2023February 28, 2027WANG, ZHOUreporter.nih.gov
Unravel a novel metabolic pathway orchestrating prostate cancer progression and therapeutic resistanceNIHNational Cancer Institute2023 to 2025$1,522,620January 3, 2022August 31, 2027LIN, HUI-KUANreporter.nih.gov
FOXA1 regulates cytokine signaling and immune landscape in prostate cancer through ARID1ANIHNational Cancer Institute2023 to 2025$1,517,182August 1, 2023July 31, 2028YU, JINDANreporter.nih.gov
Androgen Activation of Innate Immune Signaling to Enhance Prostate Cancer Immune ResponseNIHNational Cancer Institute2022 to 2025$1,515,269December 1, 2021November 30, 2027KACHHAP, SUSHANT KRISHNAreporter.nih.gov
The Rigor and Clinical Utility of PSMA Enriched Extracellular Vesicles for Prostate Cancer DetectionNIHNational Cancer Institute2023 to 2025$1,497,955July 12, 2023June 30, 2028PUNNEN, SANOJreporter.nih.gov
Targeting androgen receptor nuclear localization in prostate cancerNIHNational Cancer Institute2022 to 2025$1,471,591June 10, 2022May 31, 2027WANG, ZHOUreporter.nih.gov
Multimodal, Multi-scale Framework for Ethical AI Model DevelopmentNIHOffice of the Director, National Institutes of Health2025$1,464,652June 30, 2025June 29, 2027GICHOYA, JUDYreporter.nih.gov
Glutaminase I isoforms as personalized biomarkers of prostate cancerNIHNational Cancer Institute2022 to 2025$1,452,662January 1, 2022December 31, 2026HUANG, JIAOTIreporter.nih.gov
Automated Assessment for Robotic Suturing Utilizing Deep Learning AlgorithmsNIHNational Cancer Institute2023 to 2025$1,438,983April 1, 2021March 31, 2026HUNG, ANDREWreporter.nih.gov
Targeting aberrant circadian regulator in advanced prostate cancerNIHNational Cancer Institute2022 to 2025$1,436,443December 15, 2021November 30, 2026CHEN, HONGWUreporter.nih.gov
Cooperativity of TMPRSS2-ERG fusion with p53 inactivation in prostate cancer pathogenesisNIHNational Cancer Institute2022 to 2025$1,433,646March 1, 2022February 28, 2028WANG, LIEWEIreporter.nih.gov
COP1 REGULATION OF AR SIGNALING AND PROSTATE CANCER GROWTH AND THERAPY RESISTANCENIHNational Cancer Institute2023 to 2025$1,431,666May 1, 2023April 30, 2028YANG, FENGreporter.nih.gov
Targeting a Novel Signaling Nexus pACK/pCSK/pLCK in Immune Checkpoint Blockade (ICB)-Resistant Prostate CancerNIHNational Cancer Institute2023 to 2025$1,428,877July 1, 2023June 30, 2028MAHAJAN, NUPAM Preporter.nih.gov
Ethnicity-determined T cell responses and GARP/TGFbeta1 signaling in prostate cancerNIHNational Cancer Institute2022 to 2025$1,422,658December 9, 2021November 30, 2026ZI, XIAOLINreporter.nih.gov
Upstream and downstream targeting of the SPOP ubiquitin signaling pathway in prostate cancerNIHNational Cancer Institute2024 to 2025$1,421,960August 1, 2024July 31, 2029ZHOU, PENGBOreporter.nih.gov
Theranostic DLL3/PSMA-bi-specific CAR-T cells for prostate cancer therapyNIHNational Cancer Institute2024 to 2025$1,419,727September 4, 2024August 31, 2029PONOMAREV, VLADIMIRreporter.nih.gov
Characterizing the theranostic potential of DLL3-targeting agents in high-grade neuroendocrine carcinomas of the lung and prostateNIHNational Cancer Institute2024 to 2025$1,419,480July 2, 2024June 30, 2028BODEI, LISAreporter.nih.gov
Epigenetic aging as a driver of racial disparities in early onset prostate cancerNIHNational Cancer Institute2024 to 2025$1,416,138September 20, 2024August 31, 2029WOLOSZYNSKA-READ, ANNAreporter.nih.gov
Comprehensive Analyses of HOXB13-regulated Transcriptional programs critical for Prostate Cancer ProgressionNIHNational Cancer Institute2023 to 2025$1,398,942March 1, 2023February 28, 2026YU, JINDANreporter.nih.gov
ESCAPE - Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate CancerNIHNational Cancer Institute2024 to 2025$1,397,432April 1, 2024March 31, 2029MCCLURE, TIMOTHYreporter.nih.gov
Dissecting and targeting a novel vulnerability in aggressive Rb1 and p53 doubly deficient prostate cancerNIHNational Cancer Institute2022 to 2025$1,396,513August 1, 2022July 31, 2027LI, WENLIANGreporter.nih.gov
Macrocycle inhibition of beta-catenin mediated transcription in prostate cancerNIHNational Cancer Institute2024 to 2025$1,388,993June 1, 2024May 31, 2026LOGAN, SUSAN K.reporter.nih.gov
Augmenting PSMA expression to enhance PSMA directed therapeutic efficacyNIHNational Cancer Institute2024 to 2025$1,388,233February 1, 2024January 31, 2029HAFFNER, MICHAEL Creporter.nih.gov
Long-Term Mental Health Outcomes in Prostate Cancer Survivors and Their PartnersNIHNational Cancer Institute2023 to 2025$1,387,108June 21, 2022March 31, 2027CRUMP, CASEYreporter.nih.gov
Targeting early events in prostate cancer lineage plasticityNIHNational Cancer Institute2023 to 2025$1,380,656December 1, 2022November 30, 2027DEHM, SCOTT M.reporter.nih.gov
Racial Difference in Prostate CancerNIHNational Cancer Institute2021 to 2025$1,380,415April 1, 2018December 31, 2029FREEMAN, MICHAEL R.reporter.nih.gov
Regulation of Mitochondrial Metabolism by Tyr-phosphorylated ATP Synthase Alpha-Subunit and its Therapeutic Implications in Prostate CancerNIHNational Cancer Institute2023 to 2025$1,379,959April 1, 2023March 31, 2028MAHAJAN, NUPAM Preporter.nih.gov
Multimodal dendrimer theranostics targeting aggressive subtypes of prostate cancerNIHNational Cancer Institute2024 to 2025$1,367,760September 19, 2024August 31, 2029POMPER, MARTIN Greporter.nih.gov
Orally active CBP/p300 degradersNIHNational Cancer Institute2024 to 2025$1,361,184March 1, 2024February 28, 2029WANG, SHAOMENGreporter.nih.gov
Quantitative MRI to automatically delineate intraprostatic tumor for radiation therapyNIHNational Cancer Institute2024 to 2025$1,353,393July 1, 2024June 30, 2029QING, KUNreporter.nih.gov
In-Vivo Monitoring of Therapeutic Drug Transport Across Biological BarriersNIHNational Institute of General Medical Sciences2021 to 2025$1,350,201September 1, 2021September 2, 2025ARROYO CURRAS, NETZAHUALCOYOTLreporter.nih.gov
Therapeutic targeting of CD206+ TAMs to enhance adaptive and innate anti-tumor immune responses in metastatic castration-resistant prostate cancerNIHNational Cancer Institute2023 to 2025$1,348,066July 3, 2023June 30, 2028ZARIF, JELANI CHINELOreporter.nih.gov
Delineate the Role of GSTP1 in Advanced Prostate CancerNIHNational Cancer Institute2023 to 2025$1,346,711July 14, 2023May 31, 2028STOYANOVA, TANYA Ireporter.nih.gov
Elucidating alternative polyadenylation regulation during prostate cancer progression to castration-resistanceNIHNational Cancer Institute2024 to 2025$1,344,370May 1, 2024April 30, 2029HUANG, JIAOTIreporter.nih.gov
Biology and vulnerabilities of POU2F3+ tuft cell-like carcinomasNIHNational Cancer Institute2024 to 2025$1,341,635May 1, 2024April 30, 2029VAKOC, CHRISTOPHERreporter.nih.gov
Localized SDF-1 mRNA nanoparticle delivery for treating erectile dysfunction.NIHNational Institute of Diabetes and Digestive and Kidney Diseases2023 to 2025$1,338,910May 1, 2022April 30, 2027SUK, JUNG SOOreporter.nih.gov
Regulation of prostate epithelial basal cell plasticityNIHNational Cancer Institute2022 to 2025$1,329,440September 25, 2015February 28, 2027WANG, ZHUreporter.nih.gov
A novel role for EZH2 in A-to-I RNA editing in prostate cancerNIHNational Cancer Institute2024 to 2025$1,325,538February 5, 2024January 31, 2029CAO, QIreporter.nih.gov
Prostate Needle Biopsies: Impact of Preanalytical Procurement and Processing Variables on the Detection of Gene Expression Signatures of Prostate Cancer AggressivenessNIHNational Cancer Institute2022 to 2025$1,323,242June 17, 2022May 31, 2027POLLACK, ALANreporter.nih.gov
Cell Survival Advantage in Cadmium Induced CarcinogenesisNIHNational Institute of Environmental Health Sciences2021 to 2025$1,322,105July 15, 2021April 30, 2026DAMODARAN, CHENDILreporter.nih.gov
Molecular origins and evolution to treatment resistance in genitourinary cancersNIHNational Cancer Institute2022 to 2025$1,321,652August 1, 2022July 31, 2027PARK, JIHYEreporter.nih.gov
Small Molecule ERG Inhibitors for Prostate CancerNIHNational Cancer Institute2024 to 2025$1,317,983July 1, 2024June 30, 2029BUSHWELLER, JOHN HACKETTreporter.nih.gov
Development of Protein Degraders Targeting EZH2 Non-enzymatic Functions in Prostate CancerNIHNational Cancer Institute2024 to 2025$1,306,861September 1, 2024August 31, 2029YU, JINDANreporter.nih.gov
The role of focal adhesion kinase in therapy resistant prostate tumorsNIHNational Cancer Institute2023 to 2025$1,304,790July 7, 2023May 31, 2028HUANG, JIAOTIreporter.nih.gov
Cause and Effect Relationships Between Glycation and the Ancestry Specific Tumor StromaNIHNational Cancer Institute2023 to 2025$1,301,277January 1, 2023December 31, 2027TURNER, DAVID PAULreporter.nih.gov
SArcopenia in Men with Prostate Cancer undergoing ADT (SAP-ADT)NIHNational Cancer Institute2024 to 2025$1,300,486January 12, 2024December 31, 2028GARCIA, JOSE M.reporter.nih.gov
Defining the Mechanistic Basis of Bacterial Androgen Production in Dampening Anti-Tumor Immunity and Promoting Resistance to Androgen Receptor Axis-Targeted Therapies for Metastatic Prostate CancerNIHNational Cancer Institute2024 to 2025$1,299,526July 1, 2024June 30, 2029SFANOS, KAREN SANDELLreporter.nih.gov
Phase 1 First in Human Trial to Assess Safety and Tolerability of the Novel ACK1 Inhibitor (R)-9b in Patients with Prostate CancerNIHNational Cancer Institute2024 to 2025$1,296,178August 15, 2024July 31, 2029MAHAJAN, NUPAM Preporter.nih.gov
Enhancing radioligand therapy for prostate cancer with biomarker and dosimetry guided personalizationNIHNational Cancer Institute2024 to 2025$1,289,060September 17, 2024August 31, 2029DEWARAJA, YUNI Kreporter.nih.gov
Preclinical phenotypic modeling of chronic urologic pelvic painNIHNational Institute of Diabetes and Digestive and Kidney Diseases2022 to 2025$1,288,473April 1, 2022March 31, 2027DEBERRY, JENNIFER Jreporter.nih.gov
The role of tumor-macrophage hybrid cells in prostate cancer metastasisNIHNational Cancer Institute2024 to 2025$1,274,336May 1, 2024April 30, 2029HUANG, TIM H.-M.reporter.nih.gov
Quantifying and Personalizing the Clinical Benefit of Metastasis-Directed Therapy in Men with De Novo Oligometastatic Prostate CancerNIHNational Cancer Institute2021 to 2025$1,267,741September 14, 2021August 31, 2028SPRATT, DANIEL EIDELBERGreporter.nih.gov
Clinical Translation of a Large Oncosome-Based Prostate Cancer Blood TestNIHNational Cancer Institute2024 to 2025$1,265,472September 1, 2024August 31, 2029DI VIZIO, DOLORESreporter.nih.gov
Computational Feature Profiling and Modeling for Prostate Cancer Detection and Risk StratificationNIHNational Cancer Institute2024 to 2025$1,261,345December 5, 2023November 30, 2028ARNOLD, COREY WELLSreporter.nih.gov
Effect of DNA repeat silencing on efficacy of ATRi in prostate cancer treatmentNIHNational Cancer Institute2023 to 2025$1,249,397April 3, 2023March 31, 2028BROWN, ERIC Jreporter.nih.gov
Elucidating a novel molecular biomarker for castration-resistant prostate cancerNIHNational Cancer Institute2023 to 2025$1,245,269September 26, 2012July 31, 2028SHARIFI, NIMAreporter.nih.gov
Glycosaminoglycan Targeting Treatment for Prostatic Hyperplasia and FibrosisNIHNational Institute of Diabetes and Digestive and Kidney Diseases2024 to 2025$1,245,000August 21, 2024June 30, 2028LOKESHWAR, VINATA Breporter.nih.gov
Harnessing low-field MRI and robotics to enable personalized incisionless prostate surgeryNIHNational Cancer Institute2024 to 2025$1,233,428June 1, 2024May 31, 2029GRISSOM, WILLIAM Areporter.nih.gov
Posttranslational modifications of glucocorticoid receptor associated with drug-resistance in prostate cancerNIHNational Cancer Institute2024 to 2025$1,230,702April 9, 2024March 31, 2029ADELAIYE-OGALA, REMIreporter.nih.gov
The Role of YY1 in Castration-Resistant Prostate CancerNIHNational Cancer Institute2023 to 2025$1,229,263July 15, 2021August 31, 2026CAI, LINGreporter.nih.gov
Developing therapies to improve enzalutamide in CRPCNIHNational Cancer Institute2023 to 2025$1,228,701December 1, 2022November 30, 2027QIAN, ZHENG DAVIDreporter.nih.gov
Multi-cohort validation of machine learning radiogenomic models (ML-RGx) to predict late toxicity in prostate cancerNIHNational Cancer Institute2024 to 2025$1,223,116July 1, 2024June 30, 2026KERNS, SARAH L.reporter.nih.gov
New Treatment Strategies and Epigenetic Biomarker for Management of BPHNIHNational Institute of Diabetes and Digestive and Kidney Diseases2024 to 2025$1,214,211September 20, 2024July 31, 2029OLUMI, ARIA Freporter.nih.gov
Therapy-induced cognitive impairment in a rat model of prostate cancerNIHNational Cancer Institute2023 to 2025$1,214,059August 1, 2023July 31, 2028MORILAK, DAVID Areporter.nih.gov
MMS22L loss and PARP inhibition in prostate cancerNIHNational Cancer Institute2023 to 2025$1,207,916April 1, 2023March 31, 2028JIA, LIreporter.nih.gov
Novel ctDNA biomarker for androgen therapy in metastatic prostate cancerNIHNational Cancer Institute2024 to 2025$1,206,494December 6, 2023November 30, 2028MAHER, CHRISTOPHER Areporter.nih.gov
Mechanisms of Androgen Receptor Inverse Agonists in Advanced Prostate CancerNIHNational Cancer Institute2024 to 2025$1,205,236July 5, 2024June 30, 2026GRYDER, BERKLEY Ereporter.nih.gov
Peptoid conjugates targeting prostate cancerNIHNational Cancer Institute2024 to 2025$1,199,699August 1, 2024July 31, 2029GARABEDIAN, MICHAEL J.reporter.nih.gov
Development of fast diffusion magnetic resonance fingerprinting of the prostate to avoid unnecessary biopsiesNIHNational Cancer Institute2024 to 2025$1,199,506July 1, 2024June 30, 2026KAYAT BITTENCOURT, LEONARDOreporter.nih.gov
Molecular features promoting sensitivity to LSD1i in castration-resistant prostate cancerNIHNational Cancer Institute2024 to 2025$1,188,864March 1, 2024February 28, 2029BRENNEN, WILLIAM NATHANIELreporter.nih.gov
Urology practice consolidation and care for men with prostate cancerNIHNational Cancer Institute2024 to 2025$1,178,696February 1, 2024January 31, 2029SHAHINIAN, VAHAKN Breporter.nih.gov
WNT5a/ROR2-Mediated Hippo Pathway Activation in Prostate CancerNIHNational Cancer Institute2023 to 2025$1,166,752June 1, 2023May 31, 2028BALK, STEVEN P.reporter.nih.gov
Fluorescence image guided surgery, adjuvant PDT, and the immune responseNIHNational Institute of Biomedical Imaging and Bioengineering2024 to 2025$1,164,624July 1, 2024April 30, 2028BASILION, JAMES PETERreporter.nih.gov
Targeting pancreatic cancer metastases with TargefrinNIHNational Cancer Institute2025$1,162,000April 30, 2024August 31, 2027BAGGIO, CARLOreporter.nih.gov
Pharmacological Jak2 inhibition to overcome androgen receptor aberrations in prostate cancerNIHNational Cancer Institute2024 to 2025$1,161,698March 1, 2022March 31, 2027NEVALAINEN, MARJA Treporter.nih.gov
Protein kinase C signaling in prostate cancer health disparitiesNIHNational Cancer Institute2024 to 2025$1,159,789June 8, 2023May 31, 2028KAZANIETZ, MARCELO G.reporter.nih.gov
VIPCare: Virtual Predictive Care workflow with EHR integrated surveillance for optimalfollow-up care management for Cancer PatientsNIHNational Cancer Institute2025$1,154,996September 1, 2023August 31, 2027BAGCHI, SUGATOreporter.nih.gov
Development of small molecule therapeutics targeting AR-V7 for prostate cancerNIHNational Cancer Institute2025$1,150,471May 2, 2024April 30, 2027AU, CHEUK MAN CHERIEreporter.nih.gov
Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through combinatorial murine studies to enable further clinical advancement in prostate tumorsNIHNational Cancer Institute2025$1,150,000August 18, 2025July 31, 2027SCHULTZ, KENNETHreporter.nih.gov
A Real-Time Hyperspectral Laparoscopic Stereo Imaging System for Robot-Assisted SurgeryNIHNational Cancer Institute2024 to 2025$1,149,405March 1, 2024August 31, 2029FEI, BAOWEIreporter.nih.gov
A novel role for EZH2 in PARP regulation and PARPi-resistance in prostate cancerNIHNational Cancer Institute2024 to 2025$1,149,396July 12, 2024June 30, 2026CAO, QIreporter.nih.gov
Overcoming Drug Resistance of Castration-Resistant Prostate CancerNIHNational Cancer Institute2022 to 2025$1,143,461September 1, 2011June 30, 2027LIU, XIAOQIreporter.nih.gov
The role of histidine phosphorylation in the DNA alkylation damage responseNIHNational Cancer Institute2023 to 2025$1,136,219February 1, 2023January 31, 2028PEI, HUADONGreporter.nih.gov
Defining Tumor Microenvironmental Mediators of Prostate Cancer Metastasis and Therapy ResistanceNIHNational Cancer Institute2024 to 2025$1,132,633July 1, 2024June 30, 2029HURLEY, PAULA JILLreporter.nih.gov
Novel Therapeutic Approaches for Aggressive Prostate CancerNIHNational Cancer Institute2023 to 2025$1,130,311June 1, 2023May 31, 2028MERCURIO, ARTHUR Mreporter.nih.gov
A translational study of a synthetic lethality interaction of CD105 and androgen receptor signaling axis for castration-resistant prostate cancer patientsNIHNational Cancer Institute2024 to 2025$1,128,792July 1, 2024June 30, 2029BHOWMICK, NEIL A.reporter.nih.gov
The role and mechanism of RNA m6A modification in the pathogenesis and drug-resistance of prostate cancerNIHNational Cancer Institute2023 to 2025$1,127,164April 1, 2023March 31, 2028LEE, JIHOONreporter.nih.gov
Hybrid Intelligence for Trustable Diagnosis And Patient Management of Prostate Cancer (HIT-PIRADS)NIHNational Cancer Institute2023 to 2025$1,124,300June 22, 2023May 31, 2027BAGCI, ULASreporter.nih.gov
Develop novel bispecific antibody-drug conjugates against metastatic lethal prostate cancer across subtypeNIHNational Cancer Institute2024 to 2025$1,114,585April 1, 2024March 31, 2029LIU, BINreporter.nih.gov
Testing ATAD2 as a new therapeutic target for advanced prostate cancerNIHNational Cancer Institute2024 to 2025$1,110,884July 1, 2024June 30, 2029STOYANOVA, TANYA Ireporter.nih.gov
An Off-the-Shelf tumor cell vaccine with HLA-matching alleles for personalized treatment of advanced metastatic prostate cancer.NIHNational Cancer Institute2025$1,106,781September 1, 2023July 31, 2027WILLIAMS, WILLIAM VALENTINEreporter.nih.gov
Mechanisms by which histone methyltransferases regulate nuclear receptor activity and response to therapy in hormone-driven tumors.NIHNational Cancer Institute2023 to 2025$1,105,006March 16, 2023February 29, 2028TOSKA, ENEDAreporter.nih.gov
Development of a novel MYC inhibitor for cancer therapyNIHNational Cancer Institute2025$1,102,729September 12, 2025August 31, 2027VOLLRATH, BENreporter.nih.gov
Targeting angiotensin and inflammation to prevent radiotherapy-induced bladder toxicity.NIHNational Cancer Institute2024 to 2025$1,100,715August 1, 2024July 31, 2029MARPLES, BRIANreporter.nih.gov
Cis-aconitate decarboxylase (ACOD1) in PMN-MDSC and prostate cancer progressionNIHNational Cancer Institute2023 to 2025$1,093,197January 18, 2023December 31, 2027WANG, GUOCANreporter.nih.gov
Ghana IntegRative Approach to Cancer ResEarch Training: The Grace ProgramNIHNational Cancer Institute2021 to 2025$1,087,889May 19, 2021April 30, 2027YAMOAH, KOSJreporter.nih.gov
Molecular Mechanisms Underlying Luminal- Neuroendocrine TransdifferentiationNIHNational Cancer Institute2024 to 2025$1,082,472September 1, 2024August 31, 2029ZHAO, CHANGSHENGreporter.nih.gov
Regulation of Androgen Receptor by NXTAR Long non-coding RNA in Prostate Cancer and its Therapeutic ImplicationsNIHNational Cancer Institute2024 to 2025$1,079,624August 9, 2024July 31, 2029MAHAJAN, NUPAM Preporter.nih.gov
Determine the Role of Histone Methyltransferase ASH1L in Metastatic Prostate CancerNIHNational Cancer Institute2024 to 2025$1,075,398September 18, 2024August 31, 2029ZHAO, DIreporter.nih.gov
Interstitial fibroblasts drive prostate branching morphogenesisNIHNational Institute of Diabetes and Digestive and Kidney Diseases2023 to 2025$1,066,864May 1, 2023February 28, 2028STRAND, DOUGLAS WILLIAMreporter.nih.gov
Mechanisms and therapeutic targeting of lethal prostate cancer master regulator transcription factorsNIHNational Cancer Institute2024 to 2025$1,065,298March 1, 2024February 28, 2029DOMINGO-DOMENECH, JOSEP MARIAreporter.nih.gov
Elucidating the Role of Trop2 in Prostate CancerNIHNational Cancer Institute2023 to 2025$1,055,277April 1, 2025March 31, 2027STOYANOVA, TANYA Ireporter.nih.gov
Inhibiting Rev1-mediated translesion DNA synthesis for cancer therapyNIHNational Cancer Institute2024 to 2025$1,043,520January 1, 2024November 30, 2028HONG, JIYONGreporter.nih.gov
Defining the Biological Arc of Grade Group 1 Prostate CancerNIHNational Cancer Institute2023 to 2025$1,039,044August 1, 2023July 31, 2028SALAMI, SIMPA SAMUELreporter.nih.gov
Validation, Calibration, and Translation of Restriction Spectrum Imaging Signal Maps to enhance MRI diagnostic capabilities in Prostate CancerNIHNational Cancer Institute2024 to 2025$1,035,539May 17, 2023June 30, 2028LISS, MICHAEL ANDREreporter.nih.gov
Prescription exercise for Older men with Urinary Disease (PROUD) pilot studyNIHNational Institute of Diabetes and Digestive and Kidney Diseases2023 to 2025$1,030,086May 15, 2023March 31, 2027BAUER, SCOTT RYANreporter.nih.gov
Developing New Treatment Strategies for Neuroendocrine Prostate CancerNIHNational Cancer Institute2024 to 2025$1,027,307April 1, 2024March 31, 2029ALUMKAL, JOSHI JAMESreporter.nih.gov
Neuroendocrine differentiation post anti-androgenic therapy: Role of Tribbles 2NIHNational Cancer Institute2023 to 2025$1,025,716April 20, 2023March 31, 2028GHOSH, JAGADANANDAreporter.nih.gov
Development of VNPP433-3Beta as Novel Therapeutic for All Stages of Prostrate CancerNIHNational Cancer Institute2025$1,022,522June 4, 2025May 31, 2027RAMAMURTHY, VIDYA Preporter.nih.gov
Decreased SRD5A2 and Alternative Estrogen Signaling in Prostatic Cell SurvivalNIHNational Institute of Diabetes and Digestive and Kidney Diseases2024 to 2025$1,018,167September 6, 2024June 30, 2028OLUMI, ARIA Freporter.nih.gov
Nucleic Acid Nanoparticle-based Monoclonal Antibody MimicsNIHNational Institute of Biomedical Imaging and Bioengineering2021 to 2025$1,017,571September 1, 2021August 31, 2028KHISAMUTDINOV, EMILreporter.nih.gov
Regulation of prostate organogenesis by tissue-resident macrophagesNIHNational Institute of Diabetes and Digestive and Kidney Diseases2023 to 2025$1,016,158February 1, 2023November 30, 2027SHIBATA, MAHOreporter.nih.gov
Validation of predictive liquid biomarkers for patients with metastatic prostate cancerNIHNational Cancer Institute2023 to 2025$1,011,140June 1, 2021May 31, 2027LANG, JOSHUAreporter.nih.gov
Mechanism and therapeutic targeting of castration resistance in SPOP-mutated prostate cancerNIHNational Cancer Institute2024 to 2025$999,441April 1, 2024March 31, 2029LOU, ZHENKUNreporter.nih.gov
Acupuncture for Cognitive Health in Older Survivors of Prostate Cancer (ACHIEVE)NIHNational Cancer Institute2022 to 2025$990,335August 1, 2022July 31, 2027LIOU, KEVIN Treporter.nih.gov
Genomic bases for African geo-ethnic prostate cancer health disparityNIHNational Cancer Institute2024 to 2025$987,297April 1, 2024March 31, 2029HAYES, VANESSA MARIEreporter.nih.gov
Investigating the impact of chromosomal instability on prostate cancer aggressivenessNIHNational Cancer Institute2024 to 2025$970,708July 8, 2024June 30, 2026RODRIGUEZ-BRAVO, VERONICAreporter.nih.gov
CYP17A1-independent androgen synthesis and prostate cancer resistance to next-generation hormonal therapyNIHNational Cancer Institute2023 to 2025$967,953February 1, 2022January 31, 2027SHARIFI, NIMAreporter.nih.gov
Elucidating the Role of Tryptophan Hydroxylase 1 in Neuroendocrine Prostate CancerNIHNational Cancer Institute2024 to 2025$967,136July 1, 2024June 30, 2026WU, BOYANGreporter.nih.gov
RIPK2/MKK7/c-Myc Signaling as a Therapeutic Target in Prostate Cancer MetastasisNIHNational Cancer Institute2023 to 2025$949,275August 18, 2022May 31, 2028YANG, WEIreporter.nih.gov
Mentoring in Endocrine and Cardiometabolic Abnormalities in Cancer and AgingNIHNational Institute on Aging2021 to 2025$938,505August 15, 2021April 30, 2027BASARIA, SHEHZADreporter.nih.gov
Mechanism and therapeutic targeting of abnormal androgenesis in CHD1-deficient prostate cancerNIHNational Cancer Institute2024 to 2025$904,360April 5, 2024March 31, 2029DOMINGO-DOMENECH, JOSEP MARIAreporter.nih.gov
Identifying the role of lipid accumulation and foam cells in benign prostate diseaseNIHNational Institute of Diabetes and Digestive and Kidney Diseases2024 to 2025$901,540August 27, 2024July 31, 2029POPOVICS, PETRAreporter.nih.gov
Clinical and pre-clinical investigation of extracellular vesicles as a mechanism of toxicity in the bladder of prostate cancer patients treated with radiotherapyNIHNational Cancer Institute2024 to 2025$880,945April 5, 2024March 31, 2029LEE, YI-FENreporter.nih.gov
Elucidating the Molecular Role of SYNCRIP in Prostate Cancer and AR Targeted Therapy ResistanceNIHNational Cancer Institute2024 to 2025$877,496May 1, 2021August 31, 2026MU, PINGreporter.nih.gov
Statistical modeling to support population and translational cancer researchNIHNational Cancer Institute2021 to 2025$870,818September 20, 2017August 31, 2028GULATI, ROMANreporter.nih.gov
Enhanced imaging and treatment of aggressive subtypes of prostate cancerNIHNational Cancer Institute2024 to 2025$857,013April 15, 2024May 31, 2027POMPER, MARTIN Greporter.nih.gov
Randomized Trial of Exercise Therapy on Markers of Progression in Localized Prostate CancerNIHNational Cancer Institute2025$839,781September 15, 2022July 31, 2027JONES, LEE Wreporter.nih.gov
Defining PARP Inhibitor Response and Resistance in Prostate CancerNIHNational Cancer Institute2021 to 2025$832,680July 1, 2021June 30, 2026LOMBARD, ALANreporter.nih.gov
Uncovering the heterogenous role of senescence in prostate immune suppression and tumorigenesisNIHNational Cancer Institute2024 to 2025$820,121April 1, 2024March 31, 2029RUSCETTI, MARCUS A.reporter.nih.gov
Unveiling the Role of UBE2J1 as the E2 Ubiquitin Conjugating Enzyme in Androgen Receptor DegradationNIHNational Cancer Institute2024 to 2025$816,333July 15, 2024August 31, 2029MU, PINGreporter.nih.gov
Adaptive resistance to AR inhibitors in hypoxia by GPT1NIHNational Cancer Institute2023 to 2025$810,138April 18, 2023March 31, 2029QIAN, ZHENG DAVIDreporter.nih.gov
Activation of androgen biosynthesis and drug metabolism by cytochrome b5NIHNational Institute of General Medical Sciences2021 to 2025$803,408September 30, 2009July 31, 2029AUCHUS, RICHARD J.reporter.nih.gov
Leveraging implementation science to accelerate adoption of shorter-course radiation for breast and prostate cancerNIHNational Cancer Institute2022 to 2025$789,098December 1, 2022November 30, 2025GILLESPIE, ERIN FAYEreporter.nih.gov
Arsenic and other co-metals in the San Carlos Apache drinking waterNIHNational Cancer Institute2021 to 2025$785,110September 1, 2021August 31, 2026SAMUEL-NAKAMURA, CHRISTINEreporter.nih.gov
Integrative Approach to Comprehensive Analysis of High Throughput Data on a Cancer Center LevelNIHNational Cancer Institute2021 to 2025$751,310September 15, 2016August 31, 2026KOSSENKOV, ANDREW Vreporter.nih.gov
Improving Patient-Centered Decision-Making for Stress Urinary Incontinence Treatment in Older MenNIHNational Institute on Aging2023 to 2025$749,152September 1, 2023May 31, 2028HAMPSON, LINDSAY ANNreporter.nih.gov
Molecular Phenotyping and Image-Guidance for Surgical Treatment of High-Risk Prostate Cancer Using Ultrasmall Silica NanoparticlesNIHNational Cancer Institute2023 to 2025$749,015December 1, 2023November 30, 2026BRADBURY, MICHELLE Sreporter.nih.gov
Cancer Detection & Diagnosis Research-2022-Comprehensive genomic profiling of aggressive hormone sensitive prostate cancerNIHNational Cancer Institute2023 to 2025$747,936May 1, 2020March 31, 2026SWEENEY, CHRISTOPHER Jreporter.nih.gov
Enabling Technology to Study Mechanosensitive and Mechanoresistant Cancer Cells in FlowNIHNational Cancer Institute2024 to 2025$744,769August 1, 2021July 31, 2026KING, MICHAEL R.reporter.nih.gov
Cardiovascular Risk Prediction and Reduction in Men with Prostate CancerNIHNational Heart, Lung, and Blood Institute2025$738,472September 25, 2025August 31, 2029KY, BONNIEreporter.nih.gov
Men of African Ancestry are primed for aggressive prostate cancer by high prostate androgens driven by vitamin D deficiency and megalinNIHNational Cancer Institute2024 to 2025$735,579May 8, 2024April 30, 2029NONN, LARISAreporter.nih.gov
Dissecting mechanisms of sensitivity to B7-H3 (CD276)-targeted therapeutics in prostate cancer (PC)NIHNational Cancer Institute2024 to 2025$728,367April 1, 2024March 31, 2029HWANG, JUSTIN H.reporter.nih.gov
Treg functional changes: a novel immune regulatory effect underlying the benefit of statin drug use on lethal prostate cancerNIHNational Cancer Institute2022 to 2025$723,167March 9, 2020February 28, 2027MARRONE, MICHAEL THOMASreporter.nih.gov
Critical Resources Provided by UNMC RAP Biorepository Stimulate Cancer ResearchNIHNational Cancer Institute2021 to 2025$722,997September 15, 2016August 31, 2026GRANDGENETT, PAUL Mreporter.nih.gov
Reducing toxicity from prostate cancer radiotherapy through genetics and technologyNIHNational Cancer Institute2024 to 2025$720,562July 1, 2024June 30, 2029KISHAN, AMAR Ureporter.nih.gov
Characterizing genetic risk of cancer across diverse populations through multi-ancestry epigenome profiling and chromatin QTL discoveryNIHNational Cancer Institute2025$720,252April 1, 2025March 31, 2030BACA, SYLVAN C.reporter.nih.gov
Artificial intelligence enabled Stroma-Weighted Automated Grading system to improve risk stratification in Black MenNIHNational Cancer Institute2025$717,667March 12, 2025February 28, 2030TEWARI, ASHUTOSH Kreporter.nih.gov
Roles of TIMELESS in oncogene-induced senescence and oncogenic transformationNIHNational Cancer Institute2024 to 2025$717,404August 16, 2024July 31, 2029KIM, HYUNGJINreporter.nih.gov
Molecular Profiling of the Tumor Microenvironment in Prostate Cancer ProgressionNIHNational Cancer Institute2025$714,317August 1, 2025July 31, 2030KYPRIANOU, NATASHAreporter.nih.gov
Investigating luminal plasticity in prostate tumorigenesisNIHNational Cancer Institute2024 to 2025$711,250May 28, 2024April 30, 2029TALOS, FLAMINIAreporter.nih.gov
Family RESPOND: Defining the Genetic Basis of Prostate Cancer Risk in African American FamiliesNIHNational Cancer Institute2025$704,882April 1, 2025March 31, 2030HAIMAN, CHRISTOPHER ALANreporter.nih.gov
Analytic diagnosis methods for disease rulingNIHNational Cancer Institute2024 to 2025$697,507September 1, 2024August 31, 2029HUANG, YIJIANreporter.nih.gov
Exercise as Interception Therapy in Primary High Risk CancerNIHNational Cancer Institute2025$693,662September 3, 2020June 30, 2027JONES, LEE Wreporter.nih.gov
A non-invasive blood test for multi-cancer detection and determination of tissue of origin preceding overt cancer diagnosisNIHNational Cancer Institute2025$692,491May 1, 2025April 30, 2030BISSONNETTE, BRUCE MARCreporter.nih.gov
Identifying optimal dynamic strategies for prostate cancer controlNIHNational Cancer Institute2022 to 2025$688,276May 11, 2020May 31, 2027DICKERMAN, BARBRA ANNEreporter.nih.gov
The Roles of a Novel Microprotein in Wound Healing and CancerNIHNational Cancer Institute2021 to 2025$687,889September 1, 2021September 2, 2025MARTINEZ, THOMAS FARIDreporter.nih.gov
Integration of circulating tumor cell and nuclear imaging biomarkers to assess LuPSMA response and resistance in advanced prostate cancer patientsNIHNational Cancer Institute2025$684,107August 18, 2025July 31, 2030NG, SHEUNG CHEE THOMASreporter.nih.gov
The role of early oncogenic drivers in maintaining lineage fidelity in prostate cancerNIHNational Cancer Institute2025$683,979June 1, 2025April 30, 2030BARBIERI, CHRISTOPHER Ereporter.nih.gov
A Path Towards Leveraging AI to Enable Point-of-Care MR Devices for Disease DetectionNIHNational Cancer Institute2025$681,215September 1, 2025August 31, 2030CHOPRA, SUMITreporter.nih.gov
Together stronger: A family-centered lifestyle intervention for Black prostate cancer survivors and their caregiversNIHNational Cancer Institute2025$680,600September 19, 2025August 31, 2030CHO, DALNIMreporter.nih.gov
Cell-free DNA fragmentomics as prognostic and treatment resistance biomarkers in metastatic castration-resistant prostate cancerNIHNational Cancer Institute2025$680,453January 1, 2025December 31, 2029ZHAO, SHUANGreporter.nih.gov
Multimodality spatial analysis in prostate cancer to improve prognostic estimation and cast light into the black box of pathology artificial intelligence algorithmsNIHNational Cancer Institute2025$680,433January 1, 2025December 31, 2029COOPERBERG, MATTHEW Rreporter.nih.gov
Nautral products for targeting Skp2 in cancer interceptionNIHNational Cancer Institute2024 to 2025$667,250June 1, 2024April 30, 2027ZI, XIAOLINreporter.nih.gov
Aberrant Activation of Androgen Signaling Pathways in African American Prostate CancerNIHNational Cancer Institute2024 to 2025$665,870June 1, 2024December 17, 2025SUN, ZIJIEreporter.nih.gov
Proactive Outreach and Streamlined Genetic Testing in Prostate Cancer SurvivorsNIHNational Cancer Institute2025$663,383August 1, 2025July 31, 2030SCHWARTZ, MARC Dreporter.nih.gov
The BRCA Exchange Knowledgebase for Clinical Cancer GeneticsNIHNational Cancer Institute2025$660,079September 1, 2025August 31, 2030CLINE, MELISSA SUZANNEreporter.nih.gov
Racial Disparities in the Mechanisms of Prostate Cancer MetastasisNIHNational Cancer Institute2025$659,498January 1, 2025December 31, 2029MORENO, CARLOS SANCHEZreporter.nih.gov
Synthetic lethal metabolic drug combinations for castration-resistant prostate cancerNIHNational Cancer Institute2023 to 2025$657,720July 1, 2023June 30, 2028SENA, LAURA A.reporter.nih.gov
Prostate cancer risk stratification via computational 3D pathologyNIHNational Cancer Institute2025$648,439July 1, 2022June 30, 2027LIU, JONATHAN T.C.reporter.nih.gov
Etiologic Heterogeneity Between Molecular Subtypes of Prostate CancerNIHNational Cancer Institute2025$639,285August 1, 2025July 31, 2028STOPSACK, KONRAD HERMANNreporter.nih.gov
Targeting Undruggable Transcription Factor HoxB13 to Inhibit Prostate Cancer MetastasisNIHNational Cancer Institute2025$636,289January 1, 2025December 31, 2029HUANG, JIAOTIreporter.nih.gov
"Charting cellular attraction-based interactome with Multivalent Adhesive Probe AFM (MAPA)"NIHNational Cancer Institute2025$635,749September 1, 2025August 31, 2028OSMULSKI, PAWEL A.reporter.nih.gov
Ovcoming PARP Inhibitor ResistanceNIHNational Cancer Institute2025$633,705December 11, 2024November 30, 2029LOU, ZHENKUNreporter.nih.gov
RNA-binding as a new paradigm for androgen receptor-mediated prostate cancer therapeutic resistanceNIHNational Cancer Institute2025$632,906April 1, 2025March 31, 2030DONG, YANreporter.nih.gov
Mapping the epigenetic dynamics of prostate cancer progression: integrating liquid biopsies and single-cell epigenomics for early detection of lineage plasticity and clinical decision-makingNIHNational Cancer Institute2025$627,474March 1, 2025February 28, 2030FREEDMAN, MATTHEW Lreporter.nih.gov
Contribution of germline copy number variations to the susceptibility of aggressive prostate cancer in men of African and European ancestryNIHNational Cancer Institute2025$613,220February 1, 2025January 31, 2030CHEN, FEIreporter.nih.gov
Integrated Clinical-Grade genomic and pathology AI biomarkers for high-risk prostate cancerNIHNational Cancer Institute2025$603,981August 18, 2025July 31, 2030ZHAO, SHUANGreporter.nih.gov
Deep Learning-Based Treatment Planning for PSMA RPTNIHNational Cancer Institute2025$602,361January 1, 2025December 31, 2029EL FAKHRI, GEORGESreporter.nih.gov
Enhanced Clinical Decisions for Management of Benign Prostatic Hyperplasia Using Patient-Reported OutcomesNIHNational Institute of Diabetes and Digestive and Kidney Diseases2025$600,253June 1, 2025May 31, 2027GRIFFITH, JAMES WILLIAMreporter.nih.gov
New Insight of Androgen Signaling in Prostate Cancer Initiation and ProgressionNIHNational Cancer Institute2023 to 2025$596,400June 1, 2024May 31, 2028SUN, ZIJIEreporter.nih.gov
Improving outcomes of patients with advanced prostate cancer through a better understanding of provider decision-makingNIHNational Cancer Institute2022 to 2025$579,044July 1, 2022June 30, 2027KAYE, DEBORAH R.reporter.nih.gov
Planning to implement high-quality active surveillance in new-onset favorable risk prostate cancerNIHNational Cancer Institute2024 to 2025$577,585September 13, 2024November 30, 2026SALES, ANNE EVELYNreporter.nih.gov
Targeted Suppression of Microtubule Dynamics for Treatment of Metastatic Castration-Resistant Prostate CancerNIHNational Cancer Institute2025$571,271April 15, 2025March 31, 2030AZHDARINIA, ALIreporter.nih.gov
Combinational targeting histone and RNA modifications in prostate cancerNIHNational Cancer Institute2025$570,096April 9, 2025March 31, 2030CAO, QIreporter.nih.gov
Detecting prostate cancer aggressiveness using photoacoustic chemical imaging with photoacoustic spectral analysisNIHNational Cancer Institute2025$568,151February 3, 2025January 31, 2030JO, JANGGUNreporter.nih.gov
Growth suppressive and oncogenic transcriptional programs controlled by the androgen receptor in prostate cancerNIHNational Cancer Institute2025$564,543March 1, 2025February 28, 2030BARBIERI, CHRISTOPHER Ereporter.nih.gov
Developing isoform-selective Hsp90 inhibitors for monotherapy and enhanced immunotherapy against lethal prostate cancerNIHNational Cancer Institute2025$551,601June 10, 2025May 31, 2030BLAGG, BRIAN S Jreporter.nih.gov
Nuclear and non-nuclear functions of NKX3.1 in suppression of prostate cancerNIHNational Cancer Institute2025$546,133April 1, 2025March 31, 2030ABATE-SHEN, CORYreporter.nih.gov
Targeting glutamine metabolism to enhance the efficacy of radiopharmaceutical therapyNIHNational Cancer Institute2025$545,078February 1, 2025January 31, 2030RAY, SANGEETAreporter.nih.gov
Longitudinal Imaging and Liquid Biopsy Markers of Prostate Cancer Radiotherapy OutcomesNIHNational Cancer Institute2025$538,553April 1, 2025March 31, 2030POLLACK, ALANreporter.nih.gov
Regulation of androgen receptor signaling in prostate cancer by protein arginine methylationNIHNational Cancer Institute2025$536,161April 1, 2023March 31, 2028VISWANATHAN, SRINIVAS RAGHAVANreporter.nih.gov
A new and non-autonomous role of androgen signaling in prostate tumorigenesisNIHNational Cancer Institute2025$535,334January 1, 2025December 31, 2025SUN, ZIJIEreporter.nih.gov
Molecular analysis of castration sensitivity in the prostate epitheliumNIHNational Cancer Institute2025$531,825August 1, 2025July 31, 2030SHEN, MICHAEL M.reporter.nih.gov
ELUCIDATING THE FUNCTION OF P53-MEDIATED IL17RB REPRESSIONNIHNational Cancer Institute2024 to 2025$526,601December 15, 2023November 30, 2026ZHU, YANreporter.nih.gov
A New Ultrasound Probe and Robot for Prostate Biopsy and Focal TherapyNIHNational Cancer Institute2025$512,728August 1, 2025May 31, 2030STOIANOVICI, DANreporter.nih.gov
Targeting Early Drivers of Prostate Cancer Lineage PlasticityNIHNational Cancer Institute2025$509,246April 9, 2025March 31, 2030ALUMKAL, JOSHI JAMESreporter.nih.gov
Neural and Renal Contributions to Hypertension with Androgen Deprivation TherapyNIHNational Heart, Lung, and Blood Institute2023 to 2025$498,603August 1, 2023July 31, 2028BABCOCK, MATTHEW Creporter.nih.gov
Modified cardiac rehabilitation to enhance post-stroke physical and psychosocial function: does despression limit the response?NIHEunice Kennedy Shriver National Institute of Child Health & Human Development2025$492,869February 1, 2025January 31, 2030ROSS, RYANreporter.nih.gov
Regulation of mRNA homeostasis by PD-L1NIHNational Institute of General Medical Sciences2023 to 2025$492,000May 15, 2023April 30, 2027VANCUROVA, IVANAreporter.nih.gov
Prognostic Radiomic Signatures in Prostate Cancer Patients on Active SurveillanceNIHNational Cancer Institute2023 to 2025$485,100September 11, 2023August 31, 2026LUNA CASTANEDA, JOSE MARCIOreporter.nih.gov
Molecular mechanisms driving therapy-induced lineage plasticityNIHNational Cancer Institute2023 to 2025$482,175September 19, 2023August 31, 2028LINARES RODRIGUEZ, JUAN FRANCISCOreporter.nih.gov
Overcoming mechanisms of PTPN1 driving therapy- and castration- resistant prostate cancer with novel theranosticsNIHNational Cancer Institute2025$472,458December 1, 2024November 30, 2029HSIEH, JER-TSONGreporter.nih.gov
ATR Dependency as a Novel Therapeutic Target in Lethal RB Deficient ProstateCancerNIHNational Cancer Institute2023 to 2025$454,198June 8, 2020February 28, 2027ELLIS, LEIGHreporter.nih.gov
Combined inhibition of ATR and p110β as Therapy in PTEN-deficient Prostate CancerNIHNational Cancer Institute2024 to 2025$446,112March 1, 2024August 31, 2026DING, LIYAreporter.nih.gov
Targeting the Androgen Receptor to Sensitize Bladder Cancer to Immune Check Point Blockade.NIHNational Cancer Institute2024 to 2025$434,542January 1, 2024December 31, 2025MULHOLLAND, DAVIDreporter.nih.gov
Exploring SGLTs as Theranostic Targets for Cancer MetastasisNIHNational Cancer Institute2024 to 2025$434,366December 1, 2023November 30, 2025MUZIC, RAYMOND Freporter.nih.gov
Enhanced Cancer Risk Predictions in Underrepresented Populations through Robust Multi-Source Data IntegrationNIHNational Cancer Institute2025$432,304January 3, 2025December 31, 2029GU, TIANreporter.nih.gov
Tissue Engineering and Regenerative Medicine Undergraduate Research Addressing Challenges in Kidney and Urologic DiseasesNIHNational Institute of Diabetes and Digestive and Kidney Diseases2022 to 2025$431,940September 20, 2022June 30, 2027OPARA, EMMANUEL C.reporter.nih.gov
Extracellular vesicle enclosed circular RNA and interferon responses in tumor host interactions.NIHNational Cancer Institute2025$429,399August 18, 2025July 31, 2027SILVA, TAYLON FELIPEreporter.nih.gov
Noncanonical activities of SETD7 in preventing prostate cancer progression andtherapy resistanceNIHNational Cancer Institute2025$416,409December 5, 2024November 30, 2029CAI, CHANGMENGreporter.nih.gov
Targeting FOXA2/AP-1 axis to overcome lineage plasticity and therapy resistance in castration-resistant prostate cancerNIHNational Cancer Institute2025$415,902February 21, 2025January 31, 2030CAI, CHANGMENGreporter.nih.gov
Function of the METTL3-NUP93 complex-mediated nuclear export of m6A-modified mRNAs in castration-resistant prostate cancer.NIHNational Cancer Institute2025$412,955April 1, 2023January 31, 2029XU, KEXINreporter.nih.gov
Targeting tumor microenvironment-mediated radiopharmaceutical therapy resistance in prostate cancerNIHNational Cancer Institute2025$404,972August 1, 2025July 31, 2027ABT, EVAN ROBERTreporter.nih.gov
Immunotherapy of prostate cancer using an anti-CD6 monoclonal antibodyNIHNational Cancer Institute2024 to 2025$401,115February 15, 2024January 31, 2026FOX, DAVID ALANreporter.nih.gov
Transforming prostate cancer diagnosis: Feasibility testing of a novel system for integrated endorectal MRI and in-bore biopsyNIHNational Cancer Institute2025$399,995September 2, 2025August 31, 2027DUFRESNE, ROBERT DUFFYreporter.nih.gov
Epithelial-Mesenchymal Transition Signature Markers (EMTsm) with Machine Learning-Based Analysis as a Predictor of Metastatic Prostate CancerNIHNational Cancer Institute2025$399,954July 1, 2025June 30, 2027HOMAN, HARVEY Dreporter.nih.gov
Investigating Abbapolin PLK1 Polo Box Domain inhibitors as potential therapeutics for colorectal cancersNIHNational Cancer Institute2025$395,724August 1, 2025July 31, 2026MCINNES, CAMPBELLreporter.nih.gov
Targeting drivers of tumor heterogeneity to block the progression to neuroendocrine prostate cancerNIHNational Cancer Institute2024 to 2025$393,490July 1, 2024June 30, 2027BRADY, NICHOLAS JAMESreporter.nih.gov
Natural Language Processing Based Consultation Feedback to Improve Patient Decision Making and Physician Risk CommunicationNIHNational Cancer Institute2025$381,129January 15, 2025December 31, 2029DASKIVICH, TIMOTHYreporter.nih.gov
MENTORING IN PATIENT-ORIENTED RESEARCH IN DEEP PHENOTYPING IN CARDIO-ONCOLOGYNIHNational Heart, Lung, and Blood Institute2023 to 2025$373,889September 1, 2023August 31, 2028KY, BONNIEreporter.nih.gov
Towards characterization of Epigenetic targets in Prostate CancerNIHNational Cancer Institute2025$371,719March 1, 2025February 28, 2030ASANGANI, IRFAN AHMEDreporter.nih.gov
Activation of Drug and Biologic Conjugates by Click Chemistry and their Tumor-selective Targeting for Prostate Cancer SuppressionNIHNational Cancer Institute2024 to 2025$370,494April 1, 2024March 31, 2027CHATTERJEE, BANDANAreporter.nih.gov
Behavioral Exercise Training to Reduce Cardiovascular Disease Risk in Men Undergoing Androgen Deprivation TherapyNIHNational Heart, Lung, and Blood Institute2023 to 2025$370,227August 25, 2023July 31, 2028LUCAS, ALEXANDER RUSSELLreporter.nih.gov
Exposure to Per- and Polyfluoroalkyl Substances and Prostate Cancer: Opportunities for Prevention and Early DetectionNIHNational Institute of Environmental Health Sciences2024 to 2025$369,833March 1, 2024February 28, 2027IYER, HARI Sreporter.nih.gov
Efficient, cost-effective, and ultrasensitive sequencing of somatic mutations and methylationNIHNational Cancer Institute2025$369,468September 1, 2025August 31, 2028SALIPANTE, STEPHEN Jreporter.nih.gov
Adaptation and Testing of an Evidence-Based Sexual Health Communication Skills Training Intervention for Patients with Prostate CancerNIHNational Cancer Institute2024 to 2025$364,469September 3, 2024August 31, 2029GUPTA, NATASHAreporter.nih.gov
Studies on Lineage Plasticity in Prostate CancerNIHNational Cancer Institute2024 to 2025$360,434July 1, 2023June 30, 2028ZAIDI, SAMIRreporter.nih.gov
Subclonal p27 Loss and Altered Tumor Immune Microenvironment as a Driver of Fatal Prostate CancerNIHNational Cancer Institute2025$354,658August 1, 2025July 31, 2030SFANOS, KAREN SANDELLreporter.nih.gov
Novel multivalent PSMA-targeted taxane-conjugates for bone metastases in prostate cancerNIHNational Cancer Institute2025$353,009September 24, 2025August 31, 2026VAN, SANGreporter.nih.gov
Dissecting FOSL1-mediated lineage plasticity and resistance to androgen receptor signaling inhibition in prostate cancerNIHNational Cancer Institute2024 to 2025$346,032June 1, 2024May 31, 2027WONG, CHEN KHUANreporter.nih.gov
Novel procedure and technology for treatment of BPHNIHNational Institute of Diabetes and Digestive and Kidney Diseases2025$325,000September 15, 2025February 28, 2027SHARMA, TUSHARreporter.nih.gov
Robust and Interpretable Multimodal Machine Learning Models for Diagnosis and Prognosis of Prostate CancerNIHNational Cancer Institute2024 to 2025$308,899March 1, 2024February 28, 2029KIM, HEEJONGreporter.nih.gov
Role of Calreticulin Acetylation on Trafficking in Prostate CancerNIHNational Cancer Institute2024 to 2025$295,279August 1, 2024July 31, 2029THOMAS, COURTNEYreporter.nih.gov
DELINEATING THE ROLE OF THE HOMOCYSTEINE-FOLATE-THYMIDYLATE SYNTHASE AXIS AND URACIL ACCUMULATION IN AFRICAN AMERICAN PROSTATE TUMORSNIHNational Institute on Minority Health and Health Disparities2025$249,001July 21, 2023March 31, 2028KRIEGER, KIMIKOreporter.nih.gov
Mechanisms and vulnerabilities of ERG-driven luminal fate in prostate cancerNIHNational Cancer Institute2025$249,000April 1, 2023April 30, 2028FENG, WEIRANreporter.nih.gov
Investigating mitochondrial dysfunction in high-risk prostate cancerNIHNational Cancer Institute2025$248,847February 1, 2025January 31, 2028PAPACHRISTODOULOU, ALEXANDROSreporter.nih.gov
Integrating Radiologist Insights for Safe and Accurate AI-Assisted Prostate MRI InterpretationNIHNational Cancer Institute2025$245,087June 1, 2025May 31, 2027PENG, XIreporter.nih.gov
Guadecitabine-directed immune regulation in targeting prostate cancerNIHNational Cancer Institute2025$234,889June 1, 2025May 31, 2027KARAN, DEVreporter.nih.gov
Open-Source Software Tools for Rapid Radiofrequency Coil Modeling and Simulation in MRINIHNational Institute of Biomedical Imaging and Bioengineering2024 to 2025$232,735August 8, 2024May 31, 2026GIANNAKOPOULOS, ILIASreporter.nih.gov
Evaluating Dietary Change and a Mediterranean Diet Intervention Among Medically Underserved Men with Prostate CancerNIHNational Cancer Institute2025$210,003July 2, 2025June 30, 2030GREGG, JUSTIN Rreporter.nih.gov
The next generation of liquid biopsies: Predictive and pharmacologic biomarkersNIHNational Cancer Institute2024 to 2025$208,202September 1, 2024August 31, 2029SPERGER, JAMIE Mreporter.nih.gov
Prostate cancer-diagnosing imaging agentsNIHNational Institute of Biomedical Imaging and Bioengineering2025$205,745January 15, 2025December 31, 2027THOMAS, ALINEreporter.nih.gov
Choosing the Right BPH Procedure: Evaluating Patient Priorities and the Impact of Cost on BPH Surgical PreferenceNIHNational Institute of Diabetes and Digestive and Kidney Diseases2025$203,676August 1, 2025July 31, 2028WYMER, KEVIN Mreporter.nih.gov
Simultaneously Targeting Lineage Plasticity and Therapy Resistance Drivers Using a Novel Dual-PROTAC StrategyNIHNational Cancer Institute2025$192,564September 1, 2025August 31, 2028DENG, SUreporter.nih.gov
Enhancing Prostate Cancer Treatment Outcomes with Combined Radioimmunotherapy and Antibody Drug ConjugatesNIHNational Cancer Institute2025$185,760July 7, 2025June 30, 2027BIDKAR, ANIL PARSRAMreporter.nih.gov
Targeting the Undruggable in Castration-Resistant Prostate Cancer with FTDR-Stapled Peptide ProbesNIHNational Cancer Institute2025$177,209July 18, 2025June 30, 2027WANG, ROSSreporter.nih.gov
Racial disparities in advanced prostate cancer care: An analysis of treatment patterns and patient experienceNIHNational Cancer Institute2022 to 2025$176,696April 1, 2022May 31, 2025RENCSOK, EMILY MAEreporter.nih.gov
PSMA ligand radiosensitizers to improve the therapeutic index of external beam radiotherapy for prostate cancerNIHNational Cancer Institute2024 to 2025$176,000April 1, 2024March 31, 2026HIGGINSON, DANIELreporter.nih.gov
Unraveling myeloid-mediated mechanisms of immunotherapy resistance in prostate cancer bone metastases at single-cell resolutionNIHNational Cancer Institute2025$169,776August 1, 2025July 31, 2027LYU, ARAMreporter.nih.gov
Osteopontin: A Novel Mediator of prostatic inflammation and fibrosisNIHNational Institute of Diabetes and Digestive and Kidney Diseases2024 to 2025$158,353January 15, 2021May 31, 2025POPOVICS, PETRAreporter.nih.gov
The RNA components of the translation apparatus in prostate cancer plasticity and therapy responseNIHNational Cancer Institute2025$139,184July 1, 2025June 30, 2027KIM, YEON SOOreporter.nih.gov
Inducing Apoptosis in Castration- Resistant Prostate Cancer by Targeting Sphingomyelin Synthase 1 for mono and combination therapyNIHNational Institute of General Medical Sciences2025$138,677September 1, 2025June 30, 2029PASHIKANTI, SRINATHreporter.nih.gov
The role of loss of Y chromosome across the prostate cancer continuumNIHNational Cancer Institute2025$129,058September 1, 2025August 31, 2027WANG, ANQIreporter.nih.gov
Elucidating mechanisms of therapy response in BRCA2 mutant prostate cancersNIHNational Cancer Institute2023 to 2025$118,417August 1, 2023July 31, 2026HOFSTAD-FEIST, MIA Ereporter.nih.gov
Targeting Metabolic Vulnerabilities with Synergistic Therapeutic Agents for Treatment of Metastatic Castration-Resistant Prostate Cancer.NIHNational Cancer Institute2023 to 2025$117,901August 21, 2023August 20, 2026HACKMAN, GABRELLE LAVENDERreporter.nih.gov
Examining the role of defective oxidative phosphorylation in the normal and diseased prostateNIHNational Institute of Diabetes and Digestive and Kidney Diseases2023 to 2025$115,108April 1, 2023March 31, 2026ADRIAN, ALEXIS ELIZABETHreporter.nih.gov
Clinical risk calculator validation and implementation to optimize prostate cancer early detection in NigeriaNIHFogarty International Center2025$103,950September 16, 2025August 31, 2030TOLANI, MUSLIU ADETOLAreporter.nih.gov
Engineering Biomaterials to Modulate the Tumor Immune MicroenvironmentNIHNational Cancer Institute2025$100,760January 1, 2025December 31, 2028FIGUEROA-ESPADA, CHRISTIAN GABRIELreporter.nih.gov
Predicting prostate cancer clinical outcomes with germline genomic biomarkersNIHNational Cancer Institute2024 to 2025$83,220May 1, 2024April 30, 2027ZELTSER, NICOLEreporter.nih.gov
Optimizing PET Radio-Guided Probes for Laparoscopic Surgery: Small Compton-Angles Collimation for Increased SNR and Size and Weight ReductionNIHNational Institute of Biomedical Imaging and Bioengineering2025$80,500February 1, 2025November 30, 2026MEHADJI, BRAHIMreporter.nih.gov
The processes through which prostate cancer survivors and their partners adopt and maintain a healthy diet during prostate cancer survivorshipNIHNational Institute of Nursing Research2024 to 2025$79,978May 1, 2024January 31, 2026XU, JINGLEreporter.nih.gov
Toward Understanding the Functional Landscape of Proteolysis at the Cell SurfaceNIHNational Cancer Institute2025$75,520August 1, 2025July 31, 2028PETERS-CLARKE, TRENTONreporter.nih.gov
Understanding Prostate Resident Memory T CellsNIHNational Institute of Allergy and Infectious Diseases2024 to 2025$64,002January 1, 2024May 23, 2025TAKEHARA, KENNIDYreporter.nih.gov
Early detection of cancer using extracellular vesicle-based liquid biopsy enhanced by priming agentsNIHNational Cancer Institute2025$54,538September 1, 2025August 31, 2029KIM, DANIEL MYUNGJOONreporter.nih.gov
Deciphering the role of N6-methyladenosine (m6A) on mRNA during adaptive stressNIHNational Cancer Institute2025$49,538May 1, 2025April 30, 2028KILEDJIAN, NORAreporter.nih.gov
Cellular senescence in the pathogenesis of benign prostatic hyperplasia and associated lower urinary tract dysfunctionNIHNational Institute of Diabetes and Digestive and Kidney Diseases2025$40,384September 1, 2025August 31, 2028LIMKAR, AJINKYA RAVINDRAreporter.nih.gov
Modulation of intracellular lipid access by ATGL determines ferroptosis sensitivity in castration-resistant prostate cancerNIHNational Cancer Institute2025$39,203August 1, 2025July 31, 2027CAO, PHAM HONG ANHreporter.nih.gov
Combining antigen-specific vaccination with radiopharmaceutical therapy (RPT) to enhance anti-tumor immunity and efficacyNIHNational Cancer Institute2025$37,730July 17, 2025July 16, 2028SHIM, DAEUNreporter.nih.gov
Identifying and targeting the genetic determinants of immune suppression and immunotherapy failure in prostate cancer.NIHNational Cancer Institute2025$34,454July 20, 2025July 19, 2028MURPHY, KATHERINE C.reporter.nih.gov

Organizations

OrganizationPlaceNIH awardsNIH amountNSF awardsNSF amount
Dana-Farber Cancer InstBoston, MA11$94 million0$0
Fred Hutchinson Cancer CenterSeattle, WA11$29 million0$0
Washington UniversitySaint Louis, MO12$23.8 million0$0
Duke UniversityDurham, NC15$23.3 million0$0
University of California, San FranciscoSan Francisco, CA12$20.5 million0$0
University of Michigan at Ann ArborAnn Arbor, MI14$20.1 million0$0
University of TX MD Anderson Can CTRHouston, TX11$19.4 million0$0
Sloan-Kettering Inst Can ResearchNew York, NY11$17.4 million0$0
Johns Hopkins UniversityBaltimore, MD16$17.3 million0$0
Emory UniversityAtlanta, GA10$16.4 million0$0
Cedars-Sinai Medical CenterLos Angeles, CA10$14.6 million0$0
Stanford UniversityStanford, CA7$13.9 million0$0
Weill Medical Coll of Cornell UnivNew York, NY12$13.9 million0$0
University of KentuckyLexington, KY7$13.4 million0$0
University of Southern CaliforniaLos Angeles, CA7$13 million0$0
Mayo Clinic RochesterRochester, MN10$12.6 million0$0
Brigham and Women's HospitalBoston, MA7$12.4 million0$0
University of California Los AngelesLos Angeles, CA11$12.3 million0$0
Northwestern University at ChicagoChicago, IL7$10.8 million0$0
Oregon Health & Science UniversityPortland, OR6$10.6 million0$0
University of MinnesotaMinneapolis, MN6$10.5 million0$0
University of California at DavisDavis, CA7$10.1 million0$0
Icahn School of Medicine at Mount SinaiNew York, NY6$10 million0$0
University of ArizonaTucson, AZ2$9.9 million0$0
University of Pittsburgh at PittsburghPittsburgh, PA5$9.5 million0$0
Columbia University Health SciencesNew York, NY6$9.4 million0$0
University of Wisconsin-MadisonMadison, WI9$8.9 million0$0
University of Texas HLTH Science CenterSan Antonio, TX7$8.6 million0$0
University of UtahSalt Lake City, UT3$8.4 million0$0
Harvard University D/b/a Harvard School of Public HealthBoston, MA2$8.4 million0$0
Case Western Reserve UniversityCleveland, OH7$8.2 million0$0
Beth Israel Deaconess Medical CenterBoston, MA5$8 million0$0
Ut Southwestern Medical CenterDallas, TX6$7.9 million0$0
Roswell Park Cancer Institute CorpBuffalo, NY5$7.7 million0$0
University of Miami School of MedicineCoral Gables, FL6$6.7 million0$0
Yale UniversityNew Haven, CT7$6.7 million0$0
University of WashingtonSeattle, WA4$6.1 million0$0
Thomas Jefferson UniversityPhiladelphia, PA3$6 million0$0
University of ChicagoChicago, IL4$5.9 million0$0
New York University School of MedicineNew York, NY6$5.7 million0$0
Baylor College of MedicineHouston, TX3$5.7 million0$0
University of Nebraska Medical CenterOmaha, NE3$5.4 million0$0
Massachusetts General HospitalBoston, MA3$4.9 million0$0
University of Colorado DenverAurora, CO3$4.8 million0$0
Beckman Research Institute/city of HopeDuarte, CA4$4.8 million0$0
University of California-IrvineIrvine, CA4$4.7 million0$0
Purdue UniversityWest Lafayette, IN2$4.7 million0$0
Washington State UniversityPullman, WA3$4.6 million0$0
University of RochesterRochester, NY3$4.5 million0$0
Medical College of WisconsinMilwaukee, WI2$4.2 million0$0
Cold Spring Harbor LaboratoryCold Spring Harbor, NY2$4 million0$0
Cleveland Clinic Lerner Com-CwruCleveland, OH2$4 million0$0
Virginia Commonwealth UniversityRichmond, VA3$4 million0$0
H. Lee Moffitt Cancer CTR & Res InstTampa, FL2$3.7 million0$0
Albert Einstein College of MedicineBronx, NY4$3.7 million0$0
Texas A&m University Health Science CTRCollege Station, TX2$3.5 million0$0
University of VirginiaCharlottesville, VA3$3.5 million0$0
University of Texas HLTH Sci CTR HoustonHouston, TX3$3.4 million0$0
Ge Medical Systems Information Technologies, INCNiskayuna, NY1$3.1 million0$0
Pennsylvania State Univ Hershey Med CTRHershey, PA1$2.9 million0$0
SUNY at BuffaloAmherst, NY2$2.9 million0$0
University of PennsylvaniaPhiladelphia, PA5$2.8 million0$0
University of HawaiiHonolulu, HI1$2.8 million0$0
Boston University Medical CampusBoston, MA1$2.7 million0$0
University of Illinois at ChicagoChicago, IL2$2.5 million0$0
Indiana University IndianapolisIndianapolis, IN1$2.4 million0$0
Cancer Targeted Technology, LLCWoodinville, WA1$2.4 million0$0
SUNY at Stony BrookStony Brook, NY3$2.4 million0$0
Tulane University of LouisianaNew Orleans, LA2$2.3 million0$0
Massachusetts Institute of TechnologyCambridge, MA1$2.3 million0$0
Henry Ford Health + Michigan State University Health SciencesEast Lansing, MI1$2.3 million0$0
University of Illinois at Urbana-ChampaignUrbana, IL1$2.2 million0$0
Georgia Tech Research CorporationAtlanta, GA1$2.2 million0$0
Provincial Health Services AuthorityVancouver1$2.2 million0$0
Syntrix Biosystems, Inc.Auburn, WA1$2 million0$0
Alpenglow Biosciences, Inc.Seattle, WA1$2 million0$0
Manzanita Pharmaceuticals, Inc.Woodside, CA1$2 million0$0
University of California-Santa CruzSanta Cruz, CA2$2 million0$0
Univ of Massachusetts Med SCH WorcesterWorcester, MA3$2 million0$0
Dartmouth CollegeHanover, NH1$2 million0$0
Drexel UniversityPhiladelphia, PA1$1.9 million0$0
University of Tennessee Health Sci CTRMemphis, TN1$1.9 million0$0
Endeavor Health Clinical OperationsEvanston, IL1$1.9 million0$0
Public Health InstituteOakland, CA1$1.9 million0$0
Northwestern UniversityChicago, IL1$1.8 million0$0
Research Inst of Fox Chase Can CTRPhiladelphia, PA2$1.8 million0$0
Georgetown UniversityWashington, DC2$1.8 million0$0
Wayne State UniversityDetroit, MI1$1.8 million0$0
William Beaumont Hospital Research InstRoyal Oak, MI1$1.7 million0$0
Clark Atlanta UniversityAtlanta, GA1$1.7 million0$0
Ohio State UniversityColumbus, OH1$1.6 million0$0
Louisiana State Univ HSC ShreveportShreveport, LA1$1.6 million0$0
University of Maryland BaltimoreBaltimore, MD1$1.3 million0$0
Seattle Inst for Biomedical/clinical ResSeattle, WA1$1.3 million0$0
University of Alabama at BirminghamBirmingham, AL1$1.3 million0$0
Augusta UniversityAugusta, GA1$1.2 million0$0
Medical University of South CarolinaCharleston, SC2$1.2 million0$0
Armida Labs, Inc.San Diego, CA1$1.2 million0$0
Vizlitics Inc.Chappaqua, NY1$1.2 million0$0
Arma Bio, Inc.Tenafly, NJ1$1.2 million0$0

Funding by fiscal year

Fiscal yearNIH awardsNIH amountNSF awardsNSF amount
2025465$268,861,6970$0
2024357$187,547,8220$0
2023259$142,369,8240$0
2022160$95,000,3490$0
202198$63,934,6090$0

Open federal funding opportunities

From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.

Open opportunityNumberAgencyListingClosesAward ceilingWhy it matches
Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)PA-24-254NIHJuly 12, 2027Not listedNotice number printed on 12 awards here
NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed)PA-24-194NIHMay 7, 2027Not listedNotice number printed on 3 awards here
Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Required)PA-24-181NIHMay 8, 2027Not listedNotice number printed on 1 award here
Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed)PA-24-185NIHMay 7, 2027Not listedNotice number printed on 1 award here
Emerging Global Leader Award (K43 Independent Clinical Trial Required)PAR-24-295NIHDecember 3, 2026Not listedNotice number printed on 1 award here
NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed)PAR-27-089NIH93.395November 2, 2026Not listedSame assistance listing 93.395 as 128 awards here
Precision Approaches in Radiation Synthetic Combinations (PAIRS, RP1 Clinical Trial Optional)PAR-26-152NIH93.395November 11, 2026Not listedSame assistance listing 93.395 as 128 awards here
NCI Research Specialist Award for Core and Laboratory-based Scientists (R50 Clinical Trial Not Allowed)PAR-27-088NIH93.395November 20, 2026Not listedSame assistance listing 93.395 as 128 awards here
Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required)PAR-24-214NIH93.395January 7, 2027$375,000Same assistance listing 93.395 as 128 awards here
Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)PAR-25-079NIH93.395January 7, 2027$500,000Same assistance listing 93.395 as 128 awards here
National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)PAR-25-081NIH93.395January 7, 2027$499,999Same assistance listing 93.395 as 128 awards here
Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)RFA-CA-27-005NIH93.395January 11, 2027$700,000Same assistance listing 93.395 as 128 awards here
Single Source: Coordinating Center (CC) for the Small Cell Lung Cancer (SCLC) Consortium (U24 Clinical Trial Not Allowed)PAR-27-009NIH93.395January 25, 2027Not listedSame assistance listing 93.395 as 128 awards here
Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)RFA-CA-26-010NIH93.395January 25, 2027Not listedSame assistance listing 93.395 as 128 awards here
Radiation Oncology-Biology Integration Network (ROBIN) Centers (U54 Clinical Trial Required)RFA-CA-27-003NIH93.395January 25, 2027Not listedSame assistance listing 93.395 as 128 awards here
NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)PA-27-100NIH93.395April 5, 2027Not listedSame assistance listing 93.395 as 128 awards here
NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)PA-27-102NIH93.395April 5, 2027Not listedSame assistance listing 93.395 as 128 awards here
Advanced Development and Sustainment of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)RFA-CA-28-003NIH93.395June 11, 2027$600,000Same assistance listing 93.395 as 128 awards here
Successor-in-Interest (Type 6 Parent Clinical Trial Optional)PA-24-253NIH93.395July 17, 2027Not listedSame assistance listing 93.395 as 128 awards here
NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)PA-25-080NIH93.395September 7, 2027Not listedSame assistance listing 93.395 as 128 awards here

Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.